


VINYLIDENE CHLORIDE and
VINYLIDENE CHLORIDE-VINYL CHLORIDE COPOLYMERSVinylidene chloride1. Chemical and Physical Data1.1 Synonyms and trade names

Chem. Abstr. Services Reg. No.: 75035-4

Chem. Abstr. Name: 1,1-Dichloroethene

1,1-Dichloroethylene; *asym*-dichloroethylene

Scenatex

1.2 Structural and molecular formulae and weight

Mol. wt: 97.0

1.3 Chemical and physical properties of the pure substance

From Weast (1976), unless otherwise specified

- (a) Description: Clear liquid with a sweet odour (Hardie, 1964; Windholz, 1976)
- (b) Boiling-point: 37°C
- (c) Melting-point: -122.1°C
- (d) Density: d^{20}_4 1.218; vapour density at 37°C, 3.4 (air = 1) (Anon., 1972)
- (e) Refractive index: n^{20}_D 1.4249
- (f) Spectroscopy data: λ vapour <200 nm; infra-red, nuclear magnetic resonance, and mass spectral data have been tabulated (Grasselli & Ritchey, 1975)
- (g) Solubility: Insoluble in water (0.04% wt/vol. at 20°C); miscible with most organic solvents (Hardie, 1964)

CONFIDENTIAL

Subject of Protective Order in
Ross v. [redacted] No. 20-4337
14th Judicial District Court
Calcasieu Parish, Louisiana

CMA 015617

- (h) Volatility: Vapour pressure is 400 mm at 14.3°C (Perry & Chilton, 1973)
- (i) Stability: Flash-point (closed cup), -17°C (Anon., 1972); easily polymerized at temperatures above 0°C in the presence of oxygen or other catalysts (Windholz, 1976)
- (j) Conversion factor: 1 ppm in air is approximately 4 mg/m³

1.4 Technical products and impurities

Vinylidene chloride is commercially available in the US with the following typical specifications: vinylidene chloride, 99.6 wt %; acetylene, 25 mg/kg max.; other chlorinated hydrocarbons, none exceeding 0.25 wt %; acidity (as hydrogen chloride), 10 mg/kg max.; peroxide (as hydrogen peroxide), 10 mg/kg max.; water, 50 mg/kg max.; and inhibitor (monomethyl ether of hydroquinone), 180 to 220 mg/kg (PPG Industries, 1975).

Typical specifications for vinylidene chloride produced in Japan are as follows: specific gravity (d_4^{20}), 1.2129; melting-point, -122.1°C; boiling-point, 33.4°C; and refractive index (n_D^{20}), 1.4249.

2. Production, Use, Occurrence and Analysis

2.1 Production and use

(a) Production

Vinylidene chloride was first prepared by Regnault in 1838 by the reaction of trichloroethane and alcoholic potassium hydroxide (Reinhardt, 1943).

Although vinylidene chloride may be prepared by several methods, it is commercially produced in the US and Japan by the dehydrochlorination (using sodium hydroxide or lime) of 1,1,2-trichloroethane, derived from ethylene dichloride. The resulting crude vinylidene chloride is purified by washing, drying, and fractional distillation. Inhibitors are normally added at this point (Wessling & Edwards, 1971).

CONFIDENTIAL
Subject to the order of the Court in
Ross v. [redacted] 1987
14th [redacted]
Calcasieu Parish, Louisiana

CMA 015618

The commercial production of vinylidene chloride was dependent on the development and commercialization of vinylidene chloride copolymers, and was first reported in the US in 1940 (US Tariff Commission, 1941).

It is estimated that two US companies produced a combined total of 70 million kg vinylidene chloride in 1976 and that one of these companies manufactured an additional 50 million kg for captive use as an unisolated intermediate in the production of 1,1,1-trichloroethane. US imports and exports of vinylidene chloride are negligible.

Vinylidene chloride has been produced commercially in Japan since 1951. In 1976, three companies produced a combined total of 28.1 million kg. Japanese imports and exports of vinylidene chloride are negligible.

(b) Use

Excluding the amount used as an unisolated intermediate in the production of 1,1,1-trichloroethane, more than 90% of the vinylidene chloride produced in the US and Japan is used in the production of copolymers of high vinylidene chloride content, the other major monomer usually being vinyl chloride. For a discussion on the uses of vinylidene chloride-vinyl chloride copolymers and other vinylidene chloride-based polymers, see p. .

The remaining 10% or less of the vinylidene chloride produced is used in the manufacture of modacrylic fibres, which are largely based on acrylonitrile with small amounts of vinylidene chloride and other monomers. For a discussion on the uses of these fibres, see "Acrylic and modacrylic fibres", p. .

The American Conference of Governmental Industrial Hygienists (ACGIH) recommends that an employee's exposure to vinylidene chloride does not exceed an eight-hour time weighted average of 40 mg/m³ (10 ppm) in the workplace air in any eight-hour work shift of a forty-hour work week. During any fifteen minute period, the ACGIH proposes an absolute ceiling concentration limit of 80 mg/m³ (20 ppm) provided the daily threshold limit value (in terms of eight-hour time weighted values) is not exceeded (ACGIH, 1976).

CONFIDENTIAL

Subject to Protective Order in
Ross v. Capore, No. 80-4337
14th Judicial District Court
Calcasieu Parish, Louisiana

CMA 015619

2.2 Occurrence

Vinylidene chloride is not known to occur as a natural product.

(a) Air

Workers involved in manufacturing facilities using vinyl chloride in polymerization processes (e.g., polyvinyl chloride) have been reported to be exposed to vinylidene chloride concentrations (Jaeger, 1976; Ott et al., 1975) in amounts of less than 20 mg/m³ (5 ppm) and most frequently to trace amounts (Kramer & Mutchler, 1972). Vinylidene chloride at levels of 8 mg/m³ (2 ppm) has also been reported to be a contaminant of submarine and at levels of 0-2 ppm of spacecraft atmospheres (Altman & Dittmer, 1966).

Emissions of vinylidene chloride in the US in 1974 have been estimated at 1.52 million kg from monomer synthesis operations (reduced to 277 thousand kg by new control technology in late 1975), 308 thousand kg from polymer synthesis operations, and 13.8 thousand kg from polymer fabrication operations (Hushon & Kornreich, 1976).

(b) Water

Vinylidene chloride has been detected in effluent discharged from chemical manufacturing plants in The Netherlands at a concentration of 32 µg/l (Eurocop-Cost, 1976) and in effluent discharged by chemical and latex manufacturing plants in the US. It has also been identified in well, river, and raw water in the US (Shackelford & Keith, 1976). The highest reported concentration of vinylidene chloride in the US finished drinking water was 0.1 µg/l (US Environmental Protection Agency, 1975).

(c) Other

Vinylidene chloride has been found as an impurity in trichloroethylene (retention volume: 0.192) (Val'sov & Bodyagin, 1970), in vinyl chloride monomer (limit of detection, 5 mg/kg) (Kiezel et al., 1975; Sassu et al., 1968), and at a level of 0.011% in commercial chloroprene (Kurginyan & Shirinyan, 1969).

Commercial household and industrial saran films have been analyzed for residual vinylidene chloride monomer. Six rolls of household film had

CONFIDENTIAL

Subject: ... in
Ross v. ... 1937
...
...
... Louisiana

CMA 015620

monomer concentrations ranging from 6.5 to 10.4 mg/kg, with an average of 8.8 mg/kg. There were no significant differences in samples taken from the beginning (outside) or the end (inside) of each roll. The industrial film showed levels ranging from 10.3 to 26.2 mg/kg with levels increasing from the beginning to the end of the roll (Birkel *et al.*, 1977).

2.3 Analysis

Vinylidene chloride has been identified in air by trapping in pyridine and colorimetric determination of the cyanine obtained by reaction with barbituric acid or aniline. The limit of detection was 10 mg/m³ (2.5 ppm) (Gronsberg, 1975).

Gas chromatography has been used to determine vinylidene chloride as an impurity (1) in trichloroethylene (Vlasov & Bodyagin, 1970) and (2) in vinyl chloride monomer (Sassu *et al.*, 1968) with a limit of detection of 5 mg/kg (Kiezel *et al.*, 1975). The same thod has been applied to the detection of free vinylidene chloride in latex (Bollini *et al.*, 1974).

Sampling techniques using activated carbon as adsorbent with subsequent solvent or thermal desorption and gas chromatographic analysis have been evaluated to determine vinylidene chloride in industrial atmospheres (Severs & Skory, 1975). A sampling technique for concentration of air pollutants including vinylidene chloride on different gas chromatography has been evaluated. The compounds were thermally desorbed and analyzed by gas chromatography using flame ionization detection; the limit of detection is 4 µg/m³ (1 ppb) (Russell, 1975).

Vinylidene chloride has been detected in saran films by gas chromatography with electron capture detection and mass spectrometry confirmation. The limit of detection of the method is 5 mg/kg (Birkel *et al.*, 1977).

CONFIDENTIAL

Subject to Protective Order in
Ross v. [redacted] No. 00-1837
14th [redacted] Court
Calcasieu Parish, Louisiana

CMA 015621

3. Biological Data Relevant to the Evaluation
of Carcinogenic Risk to Humans

3.1 Carcinogenicity and related studies in animals¹

(a) Oral administration

Rat: In a preliminary report of an ongoing study, groups of 50 male and 50 female Sprague-Dawley rats were administered 5, 10 or 20 mg/kg bw vinylidene chloride in olive oil by stomach tube once daily, 4-5 days/week, for 52 weeks; 1 carcinoma of the Zymbal gland was observed in a rat treated with the 10 mg/kg bw dose. A control group of 100 male and 100 female rats were given olive oil alone. At the time of reporting, the rats had been observed for 93 weeks after the start of treatment (Maltoni *et al.*, 1977).

(b) Inhalation exposure

Mouse: In an experiment still in progress at the time of reporting, groups of Swiss mice, 9 or 16 weeks of age, were exposed 4 hours/day, 4-5 days/week, to vinylidene chloride vapours in air at concentrations of 800, 400, 200, 100, or 40 mg/m³ (200, 100, 50, 25 or 10 ppm). Due to toxicity, mice treated with 200 (60 males and 60 females) or 100 ppm (30 males and 30 females) were exposed for only 2 days and those treated with 50 ppm (30 males and 30 females) for one week only. At the 25 ppm level, 30 males and 30 females were initially exposed and a further group of 120 male and 120 female mice was started at the same exposure level and treatment of both groups continued for 52 weeks; at the time of reporting, 98 weeks, 24/150 males and 1/150 females had developed adenocarcinomas of the kidney, often bilateral. One male had a kidney adenocarcinoma in the group treated with 50 ppm for one week. No such tumours had occurred in mice exposed to 10 ppm for 52 weeks or in 380 controls (both groups observed until 98 weeks of age) (Maltoni, 1977; Maltoni *et al.*, 1977).

¹The Working Group was aware of ongoing studies to assess the carcinogenicity of vinylidene chloride in mice by skin application¹ and in mice and rats by oral administration (IARC, 1978). The Working Group was also aware of ongoing oral (drinking-water) and inhalation studies using rats in which the data analysis was not complete (Rampy *et al.*, 1977). Further inhalation studies on two strains of rats were also incomplete (Viola & Caputo, 1977).

and s.c. injection

A group of 36 male and 36 female CD-1 mice, 2 months of age, were exposed to 220 mg/m^3 (55 ppm) vinylidene chloride in air 6 hours/day, 5 days a week for 12 months, at which time the experiment was terminated. Two males died early in the experiment and were replaced by healthy mice; 2 males were killed in the 9th month of treatment and one female during the 10th month of treatment. Bronchiolo-alveolar adenomas occurred in 6 mice and angiosarcomas of the liver occurred in 3 mice treated with vinylidene chloride; no such tumours occurred in controls. Three hepatomas and 2 skin keratoacanthomas were also reported to occur in treated mice (Lee *et al.*, 1977, 1978) [The Working Group noted the short duration of the experiment].

Rat: A group of 36 male and 36 female CD rats were exposed to vinylidene chloride in air at a concentration of 220 mg/m^3 (55 ppm) 6 hours/day, 5 days a week for up to 12 months, at which time the experiment was terminated and all survivors killed. Two rats developed angiosarcomas, one in the mesenteric lymph node and one in the subcutaneous tissue. Such tumours did not occur in controls (Lee *et al.*, 1977, 1978) [The Working Group noted the short duration of the experiment].

One group of 60 male and 60 female Sprague-Dawley rats were exposed to 800 reduced to 600 mg/m^3 (200 reduced to 150 ppm), and 4 groups of 30 female and 30 male Sprague-Dawley rats were exposed to 40, 100, 200 or 400 mg/m^3 (10, 25, 50 or 100 ppm) vinylidene chloride in air for 4 hours/day, 4-5 days a week for 52 weeks and observed for up to 82 weeks (time of reporting). The animals were 16 weeks old at the start of treatment. An increased incidence of mammary fibroadenomas and carcinomas (40-60%) was reported when compared with 100 male and 100 female controls (32%). No dose-response relation was found. In addition, one Zymbal gland carcinoma was seen in one rat treated with the 100 ppm dose (Maltoni *et al.*, 1977).

Hamster: In a study still in progress, no tumours had occurred at 74 weeks among a group of 30 male and 30 female Chinese hamsters, 28 weeks of age, exposed to 25 ppm vinylidene chloride in air 4 hours/day, 4-5 days a week for 52 weeks (Maltoni *et al.*, 1977).

CONFIDENTIAL

Subject: *[illegible]* 17
Ross v *[illegible]* 10-4337
14th Judicial District Court
Calcasieu Parish, Louisiana

CMA 015623

3.2 Other relevant biological data

The adverse biological effects of vinylidene chloride have been reviewed (EPA, 1976; Haley, 1975; Warren & Ricci, 1978).

(a) Experimental systems

Toxic effects

Results reported for acute toxicity studies on vinylidene chloride have been highly variable, the lethal concentrations are dependent on the dietary parameters (fed or fasted animals) and on the hepatic glutathione content which exhibited significant variations in diurnal rhythm (Jaeger *et al.*, 1973a, 1974). The LC_{50} by inhalation for a 4 hour exposure was 40-60 mg/l (10,000-15,000 ppm) in fed rats and 2-10 mg/l (500-2500 ppm) in fasted rats (Jaeger *et al.*, 1973b); the minimum lethal concentration was 10,000 ppm for a 24 hour exposure for fed rats (Jaeger *et al.*, 1974). The LC_{50} of vinylidene chloride for rats following exposure for 4 hours and observation for 2 weeks was 25.4 mg/l (6350 ppm) (Siegel *et al.*, 1971). The oral LD_{50} in mice was 200 mg/kg bw (Jones & Hathway, 1978a). The oral LD_{50} was 1500 mg/kg bw in normal rats and 80 mg/kg bw in adrenalectomized rats (Jenkins *et al.*, 1972). In dog, the oral minimal lethal dose was 5750 mg/kg bw and the i.v. minimal lethal dose was 225 mg/kg bw. The s.c. minimal lethal dose in rabbits was 3900 mg/kg bw (Barsoum & Saad, 1934). Death was due to vascular collapse and shock (Jaeger *et al.*, 1973b).

Inhalation studies using rats, guinea-pigs, dogs, rabbits and monkeys with exposures at mean level of 189 mg/m³ (48 ppm) for 90 days produced significant mortality and liver damage but no changes in haematological parameters (Prendergast *et al.*, 1967). Inhalation of vinylidene chloride for 20 6-hour exposures at 2 mg/l (500 ppm) caused nose irritation, reduced weight gain and hepatic histopathological changes in rats (Gage, 1970). In fasted rats exposed to 0.8 mg/l (200 ppm) for 4 hours, liver parenchymal cell injury was observed (Reynolds *et al.*, 1975).

Minimal liver changes characterized by an increase in cytoplasmic vacuolization of occasional individual hepatocytes were noted in Sprague-Dawley rats treated with 6-8 mg/kg bw/day for 90 days vinylidene chloride

CONFIDENTIAL

Subject to Protective Order in
Ross v. [redacted] 1337
14th [redacted] Court
Calcasieu Parish, Louisiana

CMA 015624

577

given at a concentration of 200 mg/l in their drinking-water. In a status report on a two-year study with male and female Sprague-Dawley rats receiving 16-40 mg/kg bw/day (200-230 mg/l), 8-20 mg/kg bw/day (100-120 mg/l) and 5-12 mg/kg bw/day (60-70 mg/l) in their drinking-water, no toxicological effects were noted except for a non-dose related decrease in survival of male rats only at 18 and 24 months. Rats exposed for 30 or 90 days to doses of 0.1-0.3 mg/l (25-75 ppm) in air showed minimal toxicological effects in the liver (Norris, 1977).

Vinylidene chloride affects the activity of several liver enzymes, notably it decreases hepatic glucose-6-phosphatase and increases serum alanine α -ketoglutarate transaminase (SALT). It increases the liver content of triglycerides and decreases that of glutathione. Decreased hepatic glutathione concentrations increase the lethality and hepatotoxicity of vinylidene chloride (Jaeger *et al.*, 1973a,c). The microsomal enzyme inducers, phenobarbital and 3-methylcholanthrene, increased the lethality of vinylidene chloride inhalation (Carlson & Fuller, 1972).

Vinyl chloride, when administered simultaneously with vinylidene chloride, prevented the injury associated with vinylidene chloride inhalation in fasted rats (Jaeger, 1975).

Various epoxides (1,1,1-trichloropropane-2,3-oxide; 2,3-epoxypropan-1-ol; styrene oxide; butadiene monoxide; and cyclohexane oxide) enhanced the hepatotoxicity of vinylidene chloride in male rats and decreased the acute oral LD₅₀ (Andersen & Jenkins, 1977).

Embryotoxicity and teratogenicity

Rats were given vinylidene chloride either as 200 mg/l in the drinking-water or as 20-160 ppm (80-640 mg/m³) 7 hours/day by inhalation on days 6-15 of gestation. Rabbits were given the same dose by inhalation on days 6-18 of gestation. No teratogenic effect was seen both in rats or rabbits. Some evidence of embryotoxicity or foetotoxicity was observed in both rats and rabbits exposed to vinylidene chloride by inhalation; these effects were associated with maternally toxic levels of exposure (Norris, 1977).

CONFIDENTIAL

Subject to Protective Order in
Ross v. Conoco, Inc., No. 90-4837
14th Judicial District Court
Calcasieu Parish, Louisiana

CMA 015625

Absorption, distribution, excretion and metabolism

In rats, as the dose level of radioactive vinylidene chloride is increased from 1-50 mg/kg bw oral, or from 0.04-0.8 mg/l (10-200 ppm) inhalation, the metabolic pathway becomes saturated so that percentage-wise, less of the dose administered is metabolized and more is eliminated via the lungs as vinylidene chloride. At the 1 mg/kg bw oral dose and the 10 ppm inhalation dose, there was no difference in elimination by fed versus fasted rats. At 50 mg/kg bw oral or 200 ppm inhalation, there was a significant increase in the excretion of vinylidene chloride via the lungs and decrease in urinary excretion of radioactivity in fed versus fasted rats (Norris, 1977). The main eliminative route for ¹⁴C-vinylidene chloride after intragastric, i.v. or i.p. administration to rats is pulmonary; both unchanged vinylidene chloride and related CO₂ are excreted by that route and other vinylidene chloride metabolites via the kidneys. Biotransformation of vinylidene chloride gives thiodihydroxyacetic acid and an N-acetyl-S-cysteinylacetyl derivative as major urinary metabolites together with substantial amounts of chloroacetic acid, dithiohydroxyacetic acid and thiohydroxyacetic acid (Jones & Hathway, 1978b).

Mice metabolize a greater proportion of an oral dose of 50 mg/kg bw vinylidene chloride than rats. Mice (but not rats) excrete a small amount of N-acetyl-S-(2-carboxymethyl)cysteine and they excrete more N-acetyl-S-cysteinylacetyl derivative than do rats (Jones & Hathway, 1978a).

Metabolic conversion of vinylidene chloride into an epoxide which can rearrange to the correspondent acyl chloride has been proposed (Henschler, 1978; Jones & Hathway, 1978a,b).

Mutagenicity and other short-term tests

Vinylidene chloride at concentrations of 2% and 20% (20,000-200,000 ppm) in air produced reverse mutations in *Salmonella typhimurium* TA100 and TA 1530 in the presence of 9000 g supernatant from liver, lung and kidneys of mice and rats (Bartsch *et al.*, 1975) and in one human liver specimen (Bartsch *et al.*, 1976). At a concentration of 5% (50000 ppm) in air, it is mutagenic in *S. typhimurium* TA1535 in the presence of a S-9 mix of liver or kidney from mice and rats pretreated with Aroclor 1254. It was weakly mutagenic in the presence of a S-9 mix of liver from a human subject who had been receiving long-term phenobarbital medication (Jones & Hathway, 1978c). Reverse mutations were induced in *Escherichia coli* K 12 by vinylidene chloride solution in the presence of liver microsomes from urine pretreated with phenobarbital (Greim *et al.*, 1975).

CMA 015626

CONFIDENTIAL

Subject to Protective Order in

Ross v. General Electric Co., No. 80-4837

1411 1st St., N.E., Wash., D.C. 20002

Callahan & Associates, Inc., Attorneys

Vinylidene chloride was not mutagenic in the dominant lethal test in male CD-1 mice exposed by inhalation to 40, 120 and 200 mg/m³ (10, 30 and 50 ppm) for 6 hours/day for 5 days (Anderson *et al.*, 1978).

(b) Humans

Acute exposure to high concentrations of vinylidene chloride in air results in central nervous system depression and narcosis. Repeated exposures to low concentrations is associated with liver and renal dysfunction. Skin contact with vinylidene chloride causes irritation which may be partly due to the hydroquinone monomethyl ether inhibitor. Contact with the eye causes conjunctivitis and transient corneal injury (Irish, 1963).

3.3 Case reports and epidemiological studies

Ott *et al.* (1976) investigated the cancer risk among a cohort of 138 workers exposed to vinylidene chloride where vinyl chloride was not used as a copolymer. The authors reported that there were no findings statistically related or individually attributed to vinylidene chloride exposure in this cohort [The Working Group noted that because 27 workers were lost to follow-up but considered alive in the analyses, and that because 55 people had less than 15 years since first exposure and only 5 deaths were observed, these factors preclude any judgement on the findings].

Vinylidene chloride-vinyl chloride copolymers

1. Chemical and Physical Data

1.1 Synonyms and trade names

Chem. Abstr. Services Reg. No.: 9011-06-7

Chem. Abstr. Name: 1,1-Dichloroethene polymer with chloroethane

Chloroethylene-1,1-dichloroethylene polymer; 1,1-dichloroethylene-mono-chloroethylene polymer; 1,1-dichloroethylene polymer with chloroethylene; vinyl chloride copolymer with vinylidene chloride; vinyl chloride-1,1-dichloroethylene copolymer; vinyl chloride-vinylidene chloride copolymer; vinyl chloride-vinylidene chloride polymer; vinylidene chloride-vinyl chloride polymer

CONFIDENTIAL

Subject: _____ in
Rcss 7 _____ 1937
14th _____
Calcasieu Parish, Louisiana

CMA 015627

Breon 202; Breon CS 100/30; Daran; Daran CR 6795H; Dow 874;
Dow Latex 874; ET 67; Geon 222; Geon 652; IKHS 1; KHS 596;
Kurehalon A0; Laplen; Latex SVKh; Polyco 2611; QX 2168;
Saran 683; Saran 746; Saran Resin 683; SP 489 SVKh 1;
SVKh 40; UF 925; Velon; VIKh 65; Viniden 60; VKhVD 40;
Winiden 60

1.2 Structural and molecular formulae and molecular weight

in combination with



1.3 Chemical and physical properties of the copolymer

- (a) Description: Crystalline or amorphous powder depending upon the content of vinylidene chloride (Anon., 1973)
- (b) Melting-point: 183-195°C (Wessling & Edwards, 1971)
- (c) Solubility: Soluble in tetrahydrofuran, 1,4-dioxane, cyclohexanone, cyclopentanone, chlorobenzene, and dichlorobenzene (Wessling & Edwards, 1971).
- (d) Stability: Resistant to sunlight and weathering; γ-rays cause cross linking and chain scission (Wessling & Edwards, 1971)

1.4 Technical products and impurities

Vinylidene chloride-vinyl chloride copolymers are commercially available in the US in several forms: resins, latexes, films, and fibres. The identity and amount of impurities in these products are not available. In general, products obtained by emulsion polymerization (i.e., latexes) have varying amounts of additives used in the polymerization process, such as initiators, activators, and surface-active agents.

CONFIDENTIAL

Subject to Protective Order in
Ross v. Campbell, et al., No. 87
14th Judicial District Court
Calcasieu Parish, Louisiana

CMA 015628

The vinylidene chloride-vinyl chloride copolymers commercially available in Japan are believed to be based on 80-90% vinylidene chloride units.

2. Production, Use, Occurrence and Analysis

2.1 Production and use

(a) Production

The polymerization of vinylidene chloride was first observed by Regnault in 1838. During the 1930's in the US, the commercial development of the polymer began. The pure homopolymer is difficult to fabricate because its softening point is very close to its decomposition point. The discovery that inclusion of small amounts of other monomers lowered the softening point led to the commercial introduction in 1940 in the US of the family of vinylidene chloride copolymers now known as saran (Gabbett & Smith, 1964). The copolymers presently of commercial interest in the US are: vinylidene chloride-vinyl chloride (Saran B), vinylidene chloride-alkyl acrylate (Saran C), and vinylidene chloride-acrylonitrile (Saran F). Because saran has now come to be a generic term in the US for copolymers of high vinylidene chloride content, and because these copolymers are also often referred to as simply 'polyvinylidene chloride', the composition of the copolymers described in the literature is not always known.

Vinylidene chloride-vinyl chloride copolymers are presently produced in the US by free radical processes emulsion or suspension. In Japan, they are produced by an emulsion process. The emulsion process produces a polymer latex which can be used directly (usually with additional stabilizing ingredients) or the polymer can be recovered, usually by coagulation with an electrolyte, followed by washing and drying. The emulsion process has the advantage of producing a higher molecular weight polymer than the suspension process and the disadvantage of the relatively high concentration of additives which may affect some of the properties of the polymer. Suspension polymerization is usually used for copolymers used as moulding and extruding resins.

~~CONFIDENTIAL~~

Subject: ~~CONFIDENTIAL~~ in 1037
 Ross: ~~CONFIDENTIAL~~
 1. ~~CONFIDENTIAL~~
 Calcasieu Parish, Louisiana

CMA 015629

Four US manufacturers now produce vinylidene chloride-vinyl chloride copolymer resins, latexes, and films, and one manufacturer produces vinylidene chloride-vinyl chloride fibre. US production of vinylidene chloride copolymers in 1977 has been estimated at 68 million kg (Anon., 1977).

Vinylidene chloride-vinyl chloride copolymers were first produced commercially in Japan in 1951. In 1976, four Japanese companies produced an estimated 31.9 million kg vinylidene chloride-vinyl chloride copolymers, 2.7 million kg of which was fibre and the remainder, latex and film.

(b) Use

Vinylidene chloride-vinyl chloride copolymers have gained wide use due to their barrier properties to water and gases, their resistance to oil, grease, chemicals, and sunlight, their flexibility, and their heat sealability. In addition, the high chlorine content imparts fire retardancy to the product.

Vinylidene chloride-vinyl chloride copolymers are used in the form of films for food packaging (the largest use); coatings for cellophane, paper and other surfaces; fibres; and tubes and pipes.

Applications for vinylidene chloride-vinyl chloride copolymers in food packaging include: household food wrap; industrial food wrap for drum liners, cheese, luncheon meat, and sausage; shrink film for beef, poultry, and cheese; and in laminations for cap liners, cosmetics, and luncheon meat. A relatively new use is in a coextruded multi-layered film of polyethylene on a vinylidene chloride-vinyl chloride copolymer core (Roth, 1976).

Vinylidene chloride-vinyl chloride copolymers are used as coatings in many applications, and as such are used in two forms: solvent-soluble resins, and water dispersions or latexes.

The solvent-soluble resins are used to coat other polymer films such as cellophane (the largest single application), paper drinking cups and plates, and paperboard cartons. Other uses include interior coatings for ship tanks, railroad tank cars, and fuel storage tanks, coatings for steel piles and structures, binders in coatings for magnetic tapes, audio tapes, video tapes, and computer tapes (Roth, 1976; Wessling & Edwards, 1971).

CONFIDENTIAL

Subject to Protective Order in
Ross v. General Electric Co., No. 87-1000
14th Judicial District, Louisiana
Calcasieu Parish, Louisiana

CMA 015630

The latexes are used for coating paper for use in packaging potato chips, pretzels, cereal, and cake mixes, for coating polypropylene and other plastics for packaging and for single serving containers; and for coating paperboard for packaging candy, baked goods, and frozen and refrigerated items. Other applications include use as binders for paints and nonwoven fabrics and as an additive to cement to make high-strength mortars and concretes (Roth, 1976; Wessling & Edwards, 1971).

Extruded fibres made from vinylidene chloride-vinyl chloride copolymer resins are used in a wide variety of applications where resistance to sunlight and chemicals is required (e.g., automotive seat covers, outdoor furniture, agricultural shade cloth, and filter fabrics) (Wessling & Edwards, 1971).

Vinylidene chloride-vinyl chloride copolymer resins are also extruded into tubes, rods, pipes, and pipe liners for use in contact with chemicals and other corrosive media (Wessling & Edwards, 1971).

The multi-layered film of polyethylene on a core of vinylidene chloride-vinyl chloride copolymer reportedly has found use in ostomy devices (Roth, 1976).

In Japan, approximately 8% of the vinylidene chloride-vinyl chloride copolymers produced are in the form of fibres used for fishing nets, interior furnishings, and construction appliances. Approximately 75% are used in film applications, 13% in latex applications, and 4% in other unspecified applications.

The US Food and Drug Administration permits the use of vinylidene chloride copolymers (including the copolymers with vinyl chloride) as components of the following products when they are intended for use in contact with food: (1) adhesives; (2) resinous and polymer coatings; (3) paper and paperboard; (4) rigid and semirigid acrylic and modified acrylic plastics; (5) polyethylene phthalate polymers; and (6) packaging material for use during the irradiation of prepackaged foods (US Food and Drug Administration, 1977).

CONFIDENTIAL

Subject of Confidential Order on
Ross v. SEC 1977
14th U.S.
Calculated 1977, 1977

CMA 015631

2.2 Occurrence

Vinylidene chloride-vinyl chloride copolymers are not known to occur as natural products.

2.3 Analysis

The analytical chemistry of vinyl polymers, including vinylidene chloride-vinyl chloride copolymers has been reviewed (Cobler et al., 1968). Methods of detecting surface finishing agents, such as vinylidene chloride polymers, on paper have been reviewed (Proksch, 1969).

Methods of identifying polymer films, including vinylidene chloride copolymers, based on physical and chemical properties have been described (Briston, 1974; Van Gieson, 1969).

3. Biological Data Relevant to the Evaluation of Carcinogenic Risk to Humans

3.1 Carcinogenicity and related studies in animals

No data were available to the Working Group.

3.2 Other relevant biological data

(a) Experimental systems

Rats fed a diet containing 5% vinyl chloride-vinylidene chloride copolymer for two years showed no toxic effects. Two dogs fed a diet containing 5% of the copolymer were also without evidence of toxic effects (Wilson & McCormick, 1954).

Rabbits treated for three months i.v. with 1 ml/kg bw 1% solution of vinylidene chloride-vinyl chloride copolymer exhibited hypertrophy of the reticulo-endothelial cells of the spleen, bone marrow, liver, lymphatic tissue and lungs (Miyasaki, 1959).

(b) Humans

One case of contact dermatitis, limited to the area of its application, has been reported from the use of Saran Wrap (a vinylidene chloride-vinyl chloride copolymer). A positive patch test to the copolymer was also obtained (Osbourn, 1964).

CONFIDENTIAL

Subject to Review by Office in
Rosa v. [redacted] No. 00-1337
1- [redacted]
Col. [redacted] Louisiana

CMA 015632

Two workers developed persistent cranial nerve disorders after cleaning-out tank cars in which an aqueous dispersion of vinylidene chloride copolymers had been transported. These were attributed to trace reaction products found in the copolymer (i.e., monochloroacetylene and/or dichloroacetylene). The trigeminal nerve was principally involved, and to a lesser degree the occipital auricular and cervical cutaneous nerves as well as the muscles of mastication, the eye muscles and the hypoglossus (Henschler et al., 1970).

3.3 Case reports and epidemiological studies

No data were available to the Working Group.

4. Summary of Data Reported and Evaluation

4.1 Experimental data

Vinylidene chloride has been tested by oral administration in rats and by inhalation exposure in mice, rats and hamsters. When given by inhalation in rats and mice, it induced malignant tumours, including angiosarcomas. The preliminary results of another inhalation study in rats and mice indicate the induction of malignant tumours of the kidney in mice, mostly males, and of an increased incidence of mammary tumours in rats. No carcinogenic effect was observed in an on-going study in hamsters exposed to vinylidene chloride by inhalation. The oral study in rats is still underway and cannot be evaluated.

Vinylidene chloride is mutagenic.

No data on the carcinogenicity of vinylidene chloride-vinyl chloride copolymer were available to the Working Group.

4.2 Human data

The production volume of vinylidene chloride is high, and the material is utilized almost entirely in the production of the copolymers. This suggests that occupationally exposed groups might be identified for epidemiological investigation. Production of the vinylidene chloride-vinyl chloride copolymer is extensive, and its use in consumer products (including food packaging) indicates the possibility of widespread human exposure.

CONFIDENTIAL

Subject to Protective Order in
Ross v. _____, No. 90-4837
14th U.S. District Court
Calcasieu Parish, Louisiana

CMA 015633

- 235

The only epidemiological study available to the Working Group reported no tumours associated with exposure to vinylidene chloride, but the data were not adequate to permit an assessment of carcinogenicity.

No case reports or epidemiological studies relevant to the carcinogenicity of vinylidene chloride-vinyl chloride copolymers were available to the Working Group.

4.3 Evaluation

The single epidemiological study on vinylidene chloride available to the Working Group was not adequate to permit an assessment of human carcinogenicity.

In view of the substantial volume of vinylidene chloride manufactured, the use of this compound in copolymers, the identification of the material in industrial emissions and in drinking water, and its presence in some trichloroethylene, some chloroprene, and in household materials, the lack of human epidemiological studies is serious.

The available experimental evidence of carcinogenicity of vinylidene chloride indicates that it produces malignant tumours in mice and rats and that some of the tumours are similar to those produced by vinyl chloride. This evidence is, however, limited by the fact that it is partly based on studies which were still in progress. An evaluation of the carcinogenicity of vinylidene chloride will be made upon completion of studies known to be underway.

CONFIDENTIAL

Subject to Protective Order in
Ross v. General Corp., No. 90-4037
14th Judicial District
Calcasieu Parish, Louisiana

CMA 015634

5. References

- ACGIH (1976) TLVs Threshold Limit Values for Chemical Substances in Workroom Air Adopted by ACGIH, Cincinnati, Ohio, American Conference of Governmental Industrial Hygienists, p. 30
- Altman, P.D. & Dittmer, D.S. (1966) Environmental Biology, Bethesda, Maryland, Federation of American Societies for Environmental Biology, pp. 326, 328
- Anon. (1972) Fire Protection Guide on Hazardous Materials, 4th ed., Boston, National Fire Protection Association, pp. 42-229, 325, 332
- Anon. (1977) Vinylidene chloride linked to cancer. Chem. Eng. News, February 28, pp. 6-7
- Andersen, M.E. & Jenkins, L.J., Jr (1977) Enhancement of 1,1-dichloroethylene hepatotoxicity by pretreatment with low molecular weight epoxides (Abstract No. 41). Toxicol. appl. Pharmacol., 41, 148
- Anderson, D., Hodge, M.C.E. & Purchase, I.F.H. (1978) Dominant lethal studies with the halogenated olfins vinyl chloride and vinylidene dichloride in male CD-1 mice. Environ. Health Perspect., 21, 71-78
- Bartsch, H., Malaveille, C., Montesano, R. & Tomatis, L. (1975) Tissue-mediated mutagenicity of vinylidene chloride and 2-chlorobutadiene in *Salmonella typhimurium*. Nature (Lond.), 255, 641-643
- Bartsch, H., Malaveille, C. & Montesano, R. (1976) The predictive value of tissue-mediated mutagenicity assay to assess the carcinogenic risk of chemicals. In: Montesano, R., Bartsch, H. & Tomatis, L., eds, Screening Tests in Chemical Carcinogenesis, Lyon, IARC Scientific Publications No. 12, pp. 467-491
- Birkel, T.J., Roach, J.A.G. & Sphon, J.A. (1977) Determination of vinylidene chloride in saran films by electron capture gas-solid chromatography and confirmation by mass spectrometry. J. Assoc. off. anal. Chem., 60, 1210-1213
- Bollini, M., Seves, A. & Focher, B. (1974) Determination of free monomers in water emulsions of synthetic polymers and copolymers. Ind. Carta, 12, 234-240 [Chem. Abstr., 81, 121672b]
- Briston, J.H. (1974) Appendix B. Identification of film materials. In: Plastics Films, New York, John Wiley and Sons, pp. 287-293
- Carlson, G.P. & Fuller, G.C. (1972) Interaction of modifiers of hepatic microsomal drug metabolism and the inhalation toxicity of 1,1-dichloroethylene. Res. Comm. Chem. Pathol. Pharmacol., 4, 553-559
- Anon. (1973) Chemical Technology (1973) Vol. VI, New York, Barnes & Noble Books, pp. 540-543

CONFIDENTIAL

Subject to Protective Order in
Ross v. Chemical Technology, No. 90-4337
14th
Cal.

CMA 015635

Sub - Project 605, Analysis of Organic Compounds in Air
USF, Management Committee

Cobler, J.G., Long, M.W. & Owens, E.G. (1968) Analytical chemistry of vinyl form-forming polymers. Sci. Technol. Polym. Films, 1, 703-812 [Chem. Abstr., 70, 78587m]

EPA (1976) Health and Environmental Impacts. Task 1. Vinylidene Chloride, EPA-360/6-76-023, Washington DC, US Environmental Protection Agency

EUROCOOP-COST (1976) A Comprehensive List of Polluting Substances Which Have Been Identified in Various Fresh Waters, Effluent Discharges, Aquatic Animals, and Plants, and Bottom Sediments, 2nd ed., EUCC/MDU/73/76, Commission of the European Communities, p. 41

Gabbett, J.F. & Smith, W.M. (1964) Chapter X. Copolymerizations employing vinyl chloride or vinylidene chloride as principal components. In: Ham, G.E., ed., Copolymerization, New York, Interscience Publishers, p. 609

Gage, J.C. (1970) The subacute inhalation toxicity of 109 industrial chemicals. Brit. J. ind. Med., 27, 1-18

Grasselli, J.G. & Ritchey, W.M. (1975) CRC Atlas of Spectral Data and Physical Constants for Organic Compounds, 2nd ed., Vol. III, Cleveland, Ohio, Chemical Rubber Co., p. 281

Greim, H., Bonse, G., Radwan, Z., Reichert, D. & Henschler, D. (1975) Mutagenicity in vitro and potential carcinogenicity of chlorinated ethylenes as a function of metabolic oxirane formation. Biochem. Pharmacol., 24, 2013-2017

Gronberg, E.S. (1975) Determination of vinylidene chloride in the air (Russ.). Gig. i Sanit., 7, 77-79

Haley, T.J. (1975) Vinylidene chloride: A review of the literature. Clin. Toxicol., 8, 633-643

Hardie, D.W.F. (1964) Chlorocarbons and chlorohydrocarbons. Dichloroethylenes. In: Kirk, R.E. & Othmer, D.V., eds, Encyclopedia of Chemical Technology, 2nd ed., Vol. 5, New York, John Wiley and Sons, pp. 178-180

Henschler, D., Broser, F. & Hopf, H.C. (1970) "Polyneuritis cranialis" durch Vergiftung mit chlorierten Acetylenen beim Umgang mit Vinylidenchlorid-Copolymeren ("Polyneuritis cranialis" following poisoning with chlorinated acetylenes while handling vinylidene copolymers). Arch. Toxkol., 26, 62-75

Henschler, D. (1978) Metabolism and mutagenicity of halogenated olefins. A comparison of structure and activity. Environ. Health Perspect., 21, 61-64

Hushon, J. & Kornreich, M. (1976) Air Pollution Assessment of Vinylidene Chloride, Springfield, Virginia, US National Technical Information Service, PB 256 738, p. 40

CONFIDENTIAL

Subject to Protective Order in
Ross v. General Ind., No. 00-4837
14th District Court
Calcasieu Parish, Louisiana

CMA 015636

Jones, B.K. & Hathway, D.E. (1978a) Differences in metabolism of vinylidene chloride between mice and rats. Br. J. Cancer, 37, 411-417

IARC (1978) Information Bulletin on the Survey of Chemicals Being Tested for Carcinogenicity, No. 7, Lyon, International Agency for Research on Cancer, pp. 70, 257, 272, 278

Irish, D.D. (1963) Aliphatic Halogenated Hydrocarbons. In: Patty, F.A., ed., Industrial Hygiene and Toxicology, Vol. II, 2nd revised ed., New York, Interscience, pp. 1305-1307

Jaeger, R.J. (1975) Vinyl chloride monomer: comments on its hepatotoxicity and interaction with 1,1-dichloroethylene. Ann. N.Y. Acad. Sci., 246, 150-151

Jaeger, R.J., Conolly, R.B. & Murphy, S.D. (1973a) Diurnal variation of hepatic glutathione concentration and its correlation with 1,1-dichloroethylene inhalation toxicity in rats. Res. Comm. chem. Pathol. Pharmacol., 6, 465-471

Jaeger, R.J., Trabulus, M.J. & Murphy, S.D. (1973b) The interaction of adrenalectomy, partial adrenal replacement therapy, and starvation with hepatotoxicity and lethality of 1,1-dichloroethylene intoxication (Abstract No. 133). Toxicol. appl. Pharmacol., 25, 491

Jaeger, R.J., Trabulus, M.J. & Murphy, S.D. (1972) Biochemical effects of 1,1-dichloroethylene in rats: comparison with carbon tetrachloride and 1,2-dichloroethylene. Toxicol. appl. Pharmacol., 24, 23, 457-467 504-510

Jaeger, R.J., Conolly, R.B. & Murphy, S.D. (1974) Effect of 18 hr fast and glutathione depletion of 1,1-dichloroethylene-induced hepatotoxicity and lethality in rats. Exp. mol. Pathol., 20, 187-198

Jenkins, L.J., Trabulus, M.J. & Murphy, S.D. (1972) Biochemical effects of 1,1-dichloroethylene in rats: comparison with carbon tetrachloride and 1,2-dichloroethylene. Toxicol. appl. Pharmacol., 23, 501-510

Jones, B.K. & Hathway, D.E. (1978a) Differences in metabolism of vinylidene chloride between mice and rats. Br. J. Cancer, 37, 411-417

Jones, B.K. & Hathway, D.E. (1978b) The biological fate of vinylidene chloride in rats. Chem.-biol. Interact., 20, 27-41

Kiezel, L., Liszka, M. & Rutkowski, M. (1975) Gas chromatographic determination of trace impurities in distillates of vinyl chloride monomer (Pól.). Chem. Anal. (Warsaw), 20, 555-562 [Chem. Abstr., 83, 212233s]

Kramer, C.G. & Mitchler, J.E. (1972) The correlation of clinical and environmental measurements for workers exposed to vinyl chloride. Am. ind. Hyg. Assoc. J., 33, 19-30

CMA 015637

Jaeger, R.J., Trabulus, M.J. & Murphy, S.D. (1973c) Biochemical effects of 1,1-dichloroethylene in rats: Dissociation of its hepatotoxicity from a superoxidative mechanism. Toxicol. appl. Pharmacol., 24, 457-467

Subject to be
Ross v. ...
14th ...
Calcasten Parish, Louisiana

Woods, J.S. (1977) Identification and quantitative determination of some impurities in chloroprene. Arm. Khim. Zh., 22, 61-63 [Chem. Abstr., 71, 29974x]

Lee, C.C., Bhandari, J.C., Winston, J.M., House, W.B., Peters, P.J., Dixon, R.L. & Woods, J.S. (1977) Inhalation toxicity of vinyl chloride and vinylidene chloride. Environ. Health Perspect., 21, 25-32

Maltoni, C. (1977) Recent findings on the carcinogenicity of chlorinated olefins. Environ. Health Perspect., 21, 1-5

Maltoni, C., Cottì, G., Morisi, L. & Chieco, P. (1977) Carcinogenicity bioassays of vinylidene chloride. Research plan and early results. Med. Lavoro, 68, 241-262

Miyasaki, K. (1959) Experimental studies on the reticulo-endothelial system by intravenous injection of high molecular synthetic vinyl compounds in rabbits. Acta Pathol. Jpn., 9, 109-131

Norris, J.M. (1977) Toxicological and pharmacokinetic studies on inhaled and ingested vinylidene chloride in laboratory animals. Presented at the 1977 TAPPI Paper Synthetics Conference in Chicago, Illinois, September 26, 1977

Osborn, R.A. (1964) Contact dermatitis caused by Saran Wrap. J. Am. med. Assoc., 188, 1159

Ott, M.G., Langner, R.R. & Horder, B.B. (1975) Vinyl chloride exposure in a controlled industrial environment. A long-term mortality experience in 594 employees. Arch. environ. Health, 30, 333-339

Ott, M.G., Fishbeck, W.A., Townsend, J.C. & Schneider, E.J. (1976) A health study of employees exposed to vinylidene chloride. J. occup. Med., 18, 735-738

Perry, R.H. & Chilton, C.H. (1973) Chemical Engineers' Handbook, 5th ed., New York, McGraw-Hill Book Co., p. 3-61

PPG Industries (1975) Vinylidene chloride, Bulletin L20A, Pittsburgh, Philadelphia

Prendergast, J.A., Jones, R.A., Jenkins, L.J., Jr & Siegel, J. (1967) Effects on experimental animals of long-term inhalation of trichloroethylene, carbon tetrachloride, 1,1,1-trichloroethane, dichlorodifluoromethane, and 1,1-dichloroethylene. Toxicol. appl. Pharmacol., 10, 270-289

Proksch, A. (1969) Determination of chemical auxiliary and finishing agents [for paper] by rapid methods (Ger.). Allg. Pap.-Rundschr., 35, 1207-1208 [Chem. Abstr., 72, 4461k]

CONFIDENTIAL

Subject to Protective Order in
Ross v. United States Court
14th Judicial District Court
Calcasieu Parish, Louisiana

CMA 015638

- Rampy, L.W., Quast, J.F., Humiston, C.G., Balmer, M.F. & Schwetz, B.A. (1977) Interim results of two-year toxicological studies in rats of vinylidene chloride incorporated in the drinking water or administered by repeated inhalation. Environ. Health Perspect., 21, 33-43
- Reinhardt, R.C. (1943) Vinylidene chloride polymers. Ind. Eng. Chem., 35, 442-448
- Reynolds, E.S., Moslen, M.T., Szabo, S., Jaeger, R.J. & Murphy, S.D. (1975) Hepatotoxicity of vinyl chloride and 1,1-dichloroethylene. Am. J. Pathol., 81, 219-236
- Roth, S.F. (1976) Saran coatings - latex or lacquer? In: Chemical Marketing and Economics Reprints, Staten Island, New York, Chemical Marketing and Economics Division of the American Chemical Society, pp. 29-36
- Russell, J.W. (1975) Analysis of air pollutants using sampling tubes and gas chromatography. Environ. Sci. Technol., 9, 1175-1178
- Sassu, G.M., Zilio-Grandi, F. & Conte, A. (1968) Gas-chromatographic determination of impurities in vinyl chloride. J. Chromatogr., 34, 394-398 [Chem. Abstr., 69, 8297x]
- Severs, L.W. & Skory, L.K. (1973) Monitoring personnel exposure to vinyl chloride, vinylidene chloride and methyl chloride in an industrial work environment. Am. Ind. Hyg. Assoc. J., 39, 669-676
- Siegel, J., Jones, R.A., Coon, R.A. & Lyon, J.P. (1971) Effects on experimental animals of acute, repeated and continuous inhalation exposure to dichloroacetylene mixtures. Toxicol. appl. Pharmacol., 18, 168-174

Simon (1977)

- Shackelford, W.M. & Keith, L.H. (1976) Frequency of Organic Compounds Identified in Water. EPA-600/4-76-062, Athens, Georgia, US Environmental Protection Agency, pp. 130, 133-~~133~~ 134 ¹³⁴
- US Environmental Protection Agency (1975) Preliminary Assessment of Suspected Carcinogens in Drinking Water, Washington DC, p. II-3
- US Food and Drug Administration (1977) ^{US Code of Federal Regulations,} Food and Drugs, Title 21, Parts 175.105, 175.300, 175.320, 175.360, 175.365, 176.170, 176.180, 177.1010, 177.1630, 178.3790, 179.45, pp. 438, 446, 452, 455, 465, 467-469, 471, 482, 486, 489, 496, 530, 596, 607-608
- US Tariff Commission (1941) Synthetic Organic Chemicals, US Production and Sales, 1940, Report No. 148, Second Series, Washington DC, US Government Printing Office, p. 58

CONFIDENTIAL

Subject to Protective Order in
Ross v. General Corp., No. 90-4837
 14th US District Court
 Calcasieu Parish, Louisiana

CMA 015639

Van Gieson, P. (1969) Here's a quick, easy way to identify films.
Package Eng., 14, 76-77 [Chem. Abstr., 71, 71274u]

Viola, P.L. & Caputo, A. (1977) Carcinogenicity studies on vinylidene chloride. Environ. Health Perspect., 21, 45-47

Vlasov, S.M. & Bodyagin, G.N. (1970) Gas chromatographic analysis of trichloroethylene (Russ.). Tr. Khim. Khim. Tekhnol., 1, 161-162
[Chem. Abstr., 75, 71124c]

Weast, R.C., ed. (1976) CRC Handbook of Chemistry and Physics, 57th ed., Cleveland, Ohio, Chemical Rubber Co., p. C-298

Wessling, R.A. & Edwards, F.G. (1971) Vinylidene chloride polymers.
In: Bikales, N.M., ed., Encyclopedia of Polymer Science and Technology, Plastics, Resins, Rubbers, Fibers, Vol. 14, New York, John Wiley and Sons, pp. 540-579

Wilson, R.H. & McCormick, W.E. (1954) Toxicology of plastics ^{and rubbers} ~~Plastomers~~ and monomers. Ind. Med. Surg., 23, 479-486

Windholz, M., ed. (1976) The Merck Index, 9th ed., Rahway, N.J., Merck & Co., p. 1283

? (1934) ?
Q. J. Pharm. Pharmacol., 7, 205

[Warren, H.S. & Rice, B.E. (1973) Vinylidene Chloride. I. An Overview. II. A Literature Collection 1947 to 1972.
Oak Ridge, Tennessee, Oak Ridge National Laboratory

CONFIDENTIAL

Subject to Protective Order in
Ross v. Conoco, Civil No. 90-4837
14th Judicial District Court
Calcasieu Parish, Louisiana

CMA 015640

DRAFT

1. Introduction

The present report deals primarily with the results of a project of integrated research designed to study the long-term effects (toxic and carcinogenic) of vinylidene chloride (VDC). The project included several experiments, in which the monomer was administered by different routes (inhalation and ingestion) at different concentrations, on three animal species (Sprague-Dawley rats, Swiss mice and Chinese hamsters). To our knowledge, this project, sponsored by several European producers of vinylidene chloride --European Study Group for VDC Toxicity (BASF AG, Dow Chemical Europe SA, I.C.I. Ltd, and Solvay et Cie) -- represents the most comprehensive study available in this area.

Moreover, in this report available studies on long-term carcinogenicity bioassays, as well as on other biological parameters concerning the behaviour and effects of VDC, performed in other laboratories and in ours, are reviewed for a better understanding of the biological action of the monomer.

2. Vinylidene chloride

Vinylidene chloride (VDC), or 1,1-dichloroethylene, $\text{CH}_2=\text{CCl}_2$, is produced in the U.S.A., Japan, and several Western European countries.

Vinylidene chloride is mainly employed for the production of poly(vinylidene chloride) (PVDC) resins and dispersions. Examples are Diofan[®] (BASF), Ixan[®] (Solvay), Saran[®] (Dow), and Viclan[®] (ICI). The most important property of PVDC is its low permeability to oxygen and moisture.

CONFIDENTIAL

Subject to the order in
Ross v. Ciba Ltd., No. 90-4837
14th Federal District Court
Calcasieu Parish, Louisiana

CMA 015641

The major use of PVDC is in the manufacture of flexible packaging for food.

The following population groups may be potentially exposed to VDC: (1) workers engaged in the production of VDC monomers; (2) workers manufacturing and processing VDC polymers on an industrial scale; (3) residents around factories producing VDC and VDC polymers; and, to a much lesser extent, (4) people undergoing contact with resins made with VDC and with materials containing these resins and (5) consumers of food preserved in packaging materials coated with VDC resins.

3. History

Up to 1974 no data were available on long-term effects of VDC.

In October 1974, at the XIth International Cancer Congress, held in Florence, Viola reported that he had observed cases of abdominal reticulosarcomas in a group of Wistar rats exposed to VDC by inhalation 4 hours daily, 5 days weekly, at 200 ppm for 5 months and subsequently at 100 ppm for 7 months. At the "Conference on Comparative Metabolism and Toxicity of Vinyl Chloride Related Compounds" held at the National Cancer Institute in Bethesda in May 1977. Viola and Caputo (1977) reported in detail the results of this experiment and moreover the results of a further experiment in which VDC was tested on Sprague-Dawley rats, at 100 ppm and 75 ppm, under the same experimental conditions. The authors concluded:

"A final statement of the pathological results must await the completion of the microscopic examination of the tissues and organs of all animals. Nevertheless, it seems clear that there is no grossly observable correlation between tumour formation and VDC inhalation."

CONFIDENTIAL

Subject to the order in
Ross v. American Cyanamid Co. 80-4837
14th U.S. District Court
Calderon, Louisiana

CMA 015642

On the basis of Viola's communication in 1974 The European producers of vinylidene chloride asked our Institute and Tumour Centre to undertake the present project of long-term carcinogenicity bioassays on VDC, which was started in the spring of 1975. From the start of the experiment it was immediately apparent that mice were more sensitive to the acute effects of VDC than rats, and male more than female mice (Maltoni et al., 1975).

At the beginning of 1977, in a series of reports (at the Accademia dei Lincei, Rome; at the International PVDC Seminar of TAPPI, Hamburg; at the American Cancer Society, New York; and at International Agency for Research on Cancer, Lyons), we reported that under our experimental conditions VDC produced kidney adenocarcinomas in male Swiss mice. These early results were then published in full (Maltoni et al., 1977 a, b).

In 1977 the interim results of a two-year toxicological study on the effects on rats of vinylidene chloride incorporated in their drinking water or administered by repeated inhalation, performed at the Toxicology Research Laboratory of Dow Chemical (Midland, USA), were given (Norris, 1977; Ramplly et al., 1977).

The research plan and results of the Dow studies were summarized as follows:

"Male and female Sprague-Dawley rats were exposed to vinylidene chloride (VDC) orally or by inhalation in two-year toxicological studies. VDC was given in the drinking water at mean $\pm$ S.D. concentrations of zero, 68 ± 13 ppm, 106 ± 22 ppm, and 220 ± 35 ppm, which produced mean $\pm$ S.D. dosage levels of zero, 5.9 ± 0.6 mg/kg, 10.0 ± 1.2 mg/kg, and 19.3 ± 2.7 mg/kg for male rats and zero, 7.5 ± 0.4 mg/kg,

Subject:
Ross 7
1470
Calcasteu Parish, Louisiana

CMA 015643

12.6 $\pm$ 1.1 mg/kg, and 25.6 $\pm$ 2.4 mg/kg for female rats. Forty-eight rats/sex/VDC level and 80 rats/sex in the control group were used in the two year study with an interim kill of an additional 10 rats/sex/level at 90 days. In the inhalation study, rats were exposed to 0, 10 or 40 ppm of VDC vapour 6 h/day, 5 days/week for 5 weeks, after which the exposure levels were changed to 0, 25, and 75 ppm of VDC. Exposure continued for a total of 18 months and the rats held for observation and additional 6 months. Interim kills occurred at 1, 6 and 12 months. A separate 90-day study using 20 rats/sex/level was conducted at 0, 25, and 75 ppm of VDC vapor. There were 86 rats/sex/level in the two-year portion of the study. The parameters monitored were: body weight, food and water consumption (drinking water study only), haematology, clinical chemistries, cytogenetics of bone marrow cells (inhalation study only), mortality, terminal organ weights, and gross and histopathology. Based on interim kills and gross pathologic observations, the main conclusions are: increased dytoplasmic vacuolation of hepatocytes was seen in the livers of rats given 200 ppm VDC in drinking water or 25 or 75 ppm VDC vapor by inhalation; based on gross tumor count, tumour incidence in VDC-exposed rats was not greater than controls."

In 1977, in two similar articles, Lee et al. (1977 a, b) reported the results of a study, supported by the National Institute of Environmental Health Sciences (USA), on the carcinogenicity of vinyl chloride and VDC in Albino CD-1 mice and CD rats. In this project, mice and rats of both sexes were exposed by inhalation to 55 ppm of VDC, 6 hours daily, 5 days weekly. Similar groups of animals were kept as controls. The study lasted 12 months. In this experiment the authors reported that they had ob-

CONFIDENTIAL
 Subject to Protective Order in
Ross v. American Cyanamid Co. No. 90-4937
 14th Judicial District Court
 Calcasieu Parish, Louisiana

CMA 015644

DRAFT

CONFIDENTIAL

3rd revision

Sept 78
of Maltoni paper

Toxicity and carcinogenicity bioassays of
vinylidene chloride. II. Chronic toxicity and
carcinogenicity.

by C. Maltoni, G. Cotti, L. Morisi, and P. Chieco

Institute of Oncology and Tumor Centre, Bologna, Italy

CONFIDENTIAL
Subject to Protective Order in
Ross v. , No. 90-4837
14th Court
Calcasieu Parish, Louisiana

CMA 015645

served 6 lung adenomas among 35 treated male mice versus 1 among 26 controls, 3 liver angiosarcomas (2 in males and 1 in females) and 3 hepatomas (2 in males and 1 in females) from 70 treated mice, versus none from 62 controls. Two haemangiosarcomas (1 of the mesenteric nodes, and 1 in subcutaneous tissue) were found in two of 71 treated rats versus none of the 70 controls. Concerning the bronchiolar adenomas and the hepatomas in mice, the authors concluded that their significance is questionable, since the tumours may occur also in untreated animals (and probably in consideration of the small number of tested animals). As far as angiosarcomas are concerned, on the basis of our experience with long-term effects of VDC, this result was unexpected by us (Maltoni et al., 1977 a, b). The possibility of unwanted exposure to vinyl chloride used in parallel experiments was discussed at Bethesda "Conference on Comparative Metabolism and Toxicity of Vinyl Chloride Related Compounds" (1977).

The compatibility of a prolonged inhalatory exposure of mice to 55 ppm of VDC with a long survival does not parallel our experience on the acute toxicity in several strains of mice (Swiss, Balb/C, C3H, C57 Black), and on the chronic toxicity in Swiss mice, which appeared to be much more sensitive to toxic effects of the monomer.

4. Planning, materials, and methods

The chambers for inhalation exposure were basically built of stainless steel and glass. The determination of VDC concentrations was carried out by gas chromatography.

For the ingestion experiments VDC was administered in olive oil by gavage with a stainless steel stomach tube.

CONFIDENTIAL

Subject to Protective Order in
Ross v. ~~_____~~ 1987
14th Federal District Court
Calcasieu Parish, Louisiana

CMA 015646

VDC was supplied and analyzed by the Central Laboratory of Solvay (Brussels). The impurities and their levels in the VDC employed were as follows:

1,1-dichloroethylene (VDC)	999.5	g/kg
1,2- <u>trans</u> -dichloroethylene	0.4	"
acetone	0.1	"
methylene chloride	0.05	"
mono and dichloroacetylene	0.02	"

As stabilizer p-methoxyphenol at 200 ppm was used.

The experiments utilized Sprague-Dawley rats, Swiss mice and Chinese hamsters. All the animals, except the hamsters, had been bred in our Institute for years, and, whatever their use, were all examined at death by complete autopsy, giving us extensive information concerning their current pathology.

The animals were weaned and classified by sex when 4-5 weeks old, at which time they were numbered by ear punch and divided into groups by litter distribution. After weaning, the animals were given drinking water ad libitum and an adequate commercial diet. The animals were kept in groups of five in [®]Makrolon* cages with tops made of stainless steel wire, but during the period of inhalatory treatment they were housed in groups of ten in stainless steel wire cages with a solid bottom of the same metal. A shallow layer of white-wood shavings served as bedding. The animals were kept in a temperature-controlled laboratory at 19-20 °C.

Five experiments were started around the same period. The plan of the experiments is given in tables 1 to 5.

*Polycarbonate

D-218

Experiment 1 (BT401) studied the effects on rats of inhalation exposure to 200 (then reduced, after two exposures, to 150 because of the strong toxic effects), 100, 50, 25, and 10 ppm of VDC, 4 hours daily, 4-5 days weekly, for 12 months. One group of animals served as control. 150 ppm was the highest tolerable dose by Sprague-Dawley rats for long-term exposure. From time to time the treatment was reduced from 5 to 4 times weekly because of early toxic effects in animals exposed to 150 ppm.

Experiment 2 (BT402) started with groups I, II, III, IV, V, and VI, and it was planned to study the effects on mice of inhalation exposure to the same range of VDC-doses as BT401. 25 ppm was found to be the highest tolerable dose by Swiss mice for long-term exposure. Doses of 200 and 100 ppm for 2 days, and of 50 ppm for 4 days (4 hours daily) caused death of a proportion of animals. When it appeared that exposure to 200, 100, and 50 ppm had to be withdrawn because of high mortality and severe toxic effects, the number of animals exposed to 25 ppm was enlarged by adding a supplementary group (IV/2), with its proper controls (group VII). In conclusion only two dose levels (10 and 25 ppm) were selected for this long-term study.

Experiment 3 (BT403) was designed to evaluate the effects of VDC on Sprague-Dawley rats by ingestion, at three dose levels: 20, 10, and 5 mg/kg body weight, once daily, 4-5 days weekly, for 52 weeks.

Experiment 4 (BT 404) was started to complement experiment BT403 with a lower dose (0.5 mg/kg body weight) once daily, 4-5 days weekly, for 52 weeks.

Subject
F-ES v. 1
14-h Jidi
Calcasieu Parish, Louisiana

CMA 015648

Experiment 5 (BOT405) was included to study the effects of VDC in Chinese hamsters at 25 ppm, which is the highest possible concentration for long-term exposure of mice and also one of the exposure levels of rats.

The animals were examined weekly, and weighed every 2 weeks during the period of treatment and monthly after the treatment was over. All the detectable gross pathological changes were recorded during the examination. All the animals were kept under observation until spontaneous death. Moribund animals were isolated, in order to avoid cannibalism.

A complete autopsy was carried out on each animal. Histological examinations were performed on the Zymbal glands, interscapular brown fat, salivary glands, tongue, lungs, liver, kidneys, spleen, stomach, different segments of the intestine, bladder, brain, bone marrow (sternum) and any other organs with pathological lesions. Furthermore, cytological examinations were carried out on the bone marrow of the femur. Histological sections were stained routinely with hematoxylin and eosin and, in particular cases, with Papanicolaou, Van Gieson, Mallory, and Gomory stains, silver stain, and Congo red. Cytological smears were stained with Giemsa and Papanicolaou stains.

Part of the results have been evaluated by statistical analysis (see Appendix).

5. Results

5.1. Chronic toxicity

The toxic effect was studied by histological examination of tissues and organs in animals that had died spontaneously. Therefore the observed changes had to be considered

Submitted in
Ross v.
14th Judicial District Court
Calcasieu Parish, Louisiana.

CMA 015649

as partly due to the treatment and partly due to spontaneous pathology and to immediate causes of death.

5.1.1. Rats

Regressive changes, such as hepatocytes vacuolisation, cloudy swelling, fatty degeneration (Fig. 1), necrobiosis, and necrosis were found in some animals, in treated as well as in control groups.

These changes were observed more frequently in rats exposed to 200-150 ppm by inhalation (57.6 %) than in controls (20.5 %).

5.1.2. Mice

Pathological changes were found in the liver and in the kidneys, both of control and treated animals.

The most frequent findings were regressive changes (hepatocytes and vacuolisation, cloudy swelling, fatty degeneration, necrobiosis and necrosis) and amyloidosis in the liver, and regressive changes (cloudy swelling and necrosis of tubular cells), amyloidosis of glomeruli, and chronic nephritis in the kidneys. The incidence of these lesions in the groups of animals treated with doses compatible with long survival (25 and 10 ppm) and controls is given in Tables 6 and 7. From these results no correlation emerges between the abovementioned changes and exposure to VDC.

A higher incidence of more pronounced regressive or phlogistic changes was found in residual parenchyma of kidneys with renal adenocarcinoma. In this situation it is not clear if these changes were due to treatment or to the presence of the tumor.

CONFIDENTIAL

Subject to Disposal Order in
Ross v. [REDACTED] 100-4337
14th [REDACTED] 1955
Calcasieu Parish, Louisiana

CMA 015650

Areas of fibrosis, with or without calcium deposits (Fig. 2), were found in the liver of some of the few animals which survived treatment at the high doses of VDC. Such lesions were not noted in control animals. They should be interpreted as reparative scars, following severe necrosis of hepatic cells.

5.1.3. Hamsters

No particular changes were found in hamsters, neither in treated nor in control groups.

5.2. Carcinogenicity

5.2.1. Rats

Different kinds of tumours were observed in rats treated by inhalation and ingestion and in the control groups, the mammary ones being the most frequent.

The incidence of the different types of neoplasias, and the distribution of the different histotypes of mammary tumours and of some biological parameters related to them, are given in Tables 8-22.

In rats exposed to VDC by inhalation (Tables 8 & 11), and increase in the incidence of mammary tumours in general, but not of carcinomas, was observed among treated animals when compared with the control. Within the treated groups no dose/response relationship effect was found. No increase of mammary tumours was observed among rats to which VDC has been given by stomach tube (Tables 13, 16, 18, and 21) (see statistical evaluation appendix).

This phenomenon has been noted in other experiments studying compounds chemically related and also related to

VDC, suggesting that this increase of mammary tumours may be due to some "non-specific factors" connected to inhalation (such as olfactory stimulation with consequent stimulation of pituitary gland).

No other relevant findings have been recorded.

5.2.2. Mice

Because of the high early mortality in the groups treated with 200, 100 and 50 ppm, the results are mainly based on the groups treated at 25 and 10 ppm and on controls.

Various types of tumours were observed in mice, the most frequent ones being kidney adenocarcinomas, mammary tumours, pulmonary adenomas and leukemias.

The incidence of these different types of tumours, and data on the histotypes of mammary neoplasias are given in Tables 23-25.

5.2.2.1. Kidney adenocarcinomas

The most important finding was the onset of kidney adenocarcinomas in mice exposed to 25 ppm of VDC. This kind of tumour was also observed in one of the survivors of the 50 ppm group. Such tumours were ^{not} found (neither in the 10 ppm group ^{and} ~~not in~~ the control groups, and they have ^{not} been noted in untreated Swiss mice of our breeding.

*total
Klinical 061578 helu*

The tumours of the kidneys were almost exclusively in males (29 of the 30).

The kidney adenocarcinomas were found in left and right kidneys. In some cases they were bilateral (Fig. 3). Often in the same kidney they appeared to be multi-

centric. At the autopsy the tumours were often quickly detected as nodules of different sizes. Often they were observed in uniformly enlarged kidneys, and also in kidneys without any peculiar gross change.

Following different histological parameters, these tumours could present all the patterns occurring in current human pathology. The three different basis classical histotypes were observed, i.e. clear, granular and dark cell carcinomas; in dark cell carcinomas, the cytoplasm could be basophilic or strongly eosinophilic (Fig. 4-12). While some tumours were rather monomorphic, others presented pleomorphism of different degree: large cells with very voluminous nuclei were frequently found (Figs. 13-15). The adenocarcinomas were found to show tubular, papillary, cystopapillary, solid, and uniform arrangements (Figs. 16-18). Several of these different patterns in different combinations could be found in the same tumour. Two of these tumours were found with metastases, one in the lung, and one in the liver.

Hyperplasia and dysplasia of tubuli were found in the kidneys of some treated male mice (Fig. 19 & 20).

5.2.2.2. Mammary tumours and lung adenomas

Mammary tumours, almost exclusively carcinomas, were found both in treated and in control groups. They were of the type usually observed in the untreated animals of our breed of mice. A higher incidence of these tumours was observed in the treated groups, without a dose/response relationship (Tables 23 & 25).

Pulmonary adenomas, some with cellular atypias, were found in treated and in control animals, with a higher incidence in the treated ones, without dose/ response relationship (Table 23).

Statistical analysis was performed to assess the significance of the differences in the incidence of mammary tumours and pulmonary adenomas in mice exposed to 25 and 10 ppm and in controls, also in relation to sex and age.

The important of analyzing these factors emerged from the following considerations:

- (1) the spontaneous incidence of these tumours varied in the two sexes;
- (2) these tumours were age-correlated, as are many other spontaneous tumours;
- (3) in experiment BT402 the survival of mice exposed to 25 and 10 ppm was higher than survival of the control groups.

The data on mortality rates and the results of statistical analysis are fully reported in the Appendix. They show:

- (1) There were some significant higher rates of mammary and pulmonary tumours in VDC-exposed groups when compared to the controls.
- (2) When the incidence of these tumours was adjusted for survival rate, the significance of the difference between treated and control groups was reduced.
- (3) No dose/response relationship could be calculated, either during the total time of the experiment or in different time intervals.
- (4) Overall there was a clear fluctuation and imbalance of this trend in the different groups.

CONFIDENTIAL

Subject _____
Ross v _____ 37
14th Judicial Circuit Court
Calcasieu Parish, Louisiana

CMA 015654

In conclusion the direct relation of this effect to VDC treatment remains open.

5.2.2.3. Leukemias

No correlation between leukemias and VDC treatment was found.

5.2.3. Hamsters

Tumours (mainly uterine carcinomas) were found in treated as well as in the control groups. Their incidence was not increased by VDC treatment.

6 Related research in our and other laboratories

6.1. Acute toxicity

In acute experiments, when VDC was administered at relatively high doses to rats, it caused changes in the liver and plasma enzymes (Jenkins et al., 1972; Jäger et al., 1972 and 1973).

In rats exposed by inhalation to 200 ppm of VDC, Jäger et al. (1975) observed a massive mid-zonal hepatic necrosis with hepatic thrombosis and chromatolysis within 2 h after a 4-h exposure. Serum transaminase and sorbitol dehydrogenase were greatly elevated at 6 h. This effect in unfed rats was associated with glutathione (GSH) depletion.

An extensive study of acute toxicity was performed in our Institute (Maltoni et al., 1975, in press), on Sprague-Dawley rats and 4 strains of mice (Swiss, Balb/C, C3H, C57 Black). From this study it emerged that mice are more sensitive than rats, and that Swiss and Balb/C mice are

Subject to review by the court in
Ross v. Conoco, Inc., No. 90-4837
14th Judicial District Court
Calcasieu Parish, Louisiana

CMA 015655

more sensitive than C3H and C57 Black mice. Apart from C3H mice, females appeared to be more resistant than males. Among the various effects observed the most prominent was necrosis, with cariorexis, in liver and in kidney. Such lesions appeared very marked and extensive in Swiss and Balb/C male mice.

6.2. Mutagenic effects

Greim et al. (1975) and Bartsch et al. (1975) obtained positive results with the Ames test. These authors pointed out some species-specific differences. VDC given alone showed no mutagenic effects on Salmonella strains. In adding a metabolic system of rat liver enzymes, small mutagenic effects could be seen. Using mouse-liver microsomes, the effects were several times greater.

These results parallel certain metabolic differences in the animal species. The ability of monooxygenases to form epoxides is twice as high in mice as in rats. In one of the further metabolic steps the epoxides can be transformed by means of epoxide hydratases to diols or other compounds: this enzyme system is seven times more reactive in rats than in mice (Oesch and Glatt, 1976); therefore, mice seem to produce much higher concentrations of reactive epoxides or their subsequent products of metabolism, which are postulated to be the possible direct active toxic components.

6.3. Cytogenetic effects

Balmer et al. (Dow/MCA, 1975) could not detect any cytogenetic effects in rats exposed 6 weeks by inhalation to VDC in air at concentrations of 25 and 75 ppm. This was confirmed by BASF (1977), where in Chinese hamsters, exposed 5 days by inhalation to 100 ppm VDC, no increase

CONFIDENTIAL

Subject to the provisions of the
Ross v. Environmental Protection Agency
14th Judicial District Court
Calcasieu Parish, Louisiana

CMA 015656

of chromosome aberrations in the bone marrow test could be found. After long-term exposure of 12 months to a concentration of 55 ppm Lee et al. (1978) could not find changes in the cytogenetic analysis of bone marrow test on rats as well as mice.

After a single oral dose of 217 mg/kg b.w. of VDC no statistically significant increase of the chromosome aberration rate was found (BASF, 1976).

On the basis of these results no cytogenetic effect of VDC could be found, either by long-term or by acute application of a high dose, in inhalation and oral studies with rodents.

6.4. Pharmacokinetic and metabolic studies

Jaeger et al. (1974) reported that the hepatotoxic effect of VDC is much higher in unfed rats than in fed rats, and that there is an inverse correlation between hepatotoxicity and the concentration of glutathione. These findings led to the hypothesis that the detoxification of VDC is primarily dependent upon the glutathione concentration.

Jaeger et al. (1977) pointed out that in unfed rats and fed rats exposed by inhalation to high doses of ^{14}C -VDC, ^{14}C radioactivity was found in various organs, particularly in kidney and in liver. The largest amount of total radioactivity was detected in the kidney of unfed rats.

^{14}C activity in liver cells was detected in mitochondrial, microsomal, and cytoplasmatic fractions. Significantly more radioactivity was found in all liver fractions of unfed rats. The administration of trichloropropane epoxide, an epoxide hydrase inhibitor, seemed to increase the toxicity of VDC significantly in unfed rats, the enhance-

CONFIDENTIAL

Submitted by: [redacted] in
Reference: 90-4837
Received by: [redacted] Court
[redacted] Louisiana

CMA 015657

ment of toxicity being proportional to the concentration of the inhibitor. This last result supports the hypothesis of the role of epoxide derivatives in toxicity of VDC.

McKenna et al. (1977) showed that in rats and mice exposed to ^{14}C -VDC, ^{14}C was covalently bound to macromolecules in liver and kidney of both species. The ^{14}C activity was higher in liver and in kidney of mice, in comparison to rats. The authors concluded that these data indicate an enhanced production of reactive metabolites of VDC in mice.

The data of Jaeger et al. and McKenna et al. bring further evidence that VDC toxicity does not correlate directly with the exposure per se, but is reflected in the balance of the amount of toxic metabolites and detoxification processes, which in turn are dependent upon many biological factors.

6.5. Epidemiological studies

In a recent study, published in November 1976, Ott et al. examined the mortality and the health control findings among 138 employees exposed to measured levels of VDC, ranging from 5 ppm to 75 ppm TWA (time weighted average), where vinyl chloride was not used as a second monomer. There were no findings in that study significantly related to VDC.

Hepatic damage was observed in 2 individuals with a positive history of ethanol consumption. The authors recommended "that additional epidemiologic data should be developed where exposure has taken place, with careful consideration given to obtaining an accurate history of alcohol consumption".

CONFIDENTIAL

Subject: _____ in
Ross v. _____ 1977
14-
Calcasten Pattern. _____

CMA 015658

D-216

In a similar study Thiess et al. (1977) reported mortality rates and health control findings of 629 employees exposed to VDC as well as to vinyl chloride and acrylonitrile. The VDC working-area concentrations were about 50 ppm (1955-1965), about 10 ppm (1965-1975), and 5-10 ppm after 1975. No significant increases in mortality or tumour incidence were found. Two lung carcinomas occurred at a very young age but with an exposure period of 14 and 25 months only (smoking habits unknown).

7 Conclusions

- (1) Kidney adenocarcinomas were observed in Swiss (almost exclusively male) mice exposed by inhalation to VDC at 50 and 25 ppm. Under our experimental conditions, 50 ppm VDC was already a near lethal dose, and 25 ppm was the highest dose compatible with long survival of the treated animals.

No renal tumours were observed in mice exposed to 10 ppm VDC or in controls.

- (2) Kidney adenocarcinomas were not observed in rats exposed to VDC by inhalation at doses from 150 to 10 ppm, or by ingestion (gavage) at doses from 20 mg to 0.5 mg/kg b.w., or in hamsters exposed by inhalation to 25 ppm.

- (3) The increase of mammary tumours in rats exposed to VDC by inhalation was not dose-related, and therefore it is difficult to evaluate its specific relation to the administration of the monomer. This phenomenon has been observed in other long-term inhalation bioassays.

CONFIDENTIAL
Subj: [illegible] 1837
Rose [illegible]
14th Judicial Dist. Court
Calcasieu Parish, Louisiana

CMA 015659

Z-215

- (4) The dependence of the increase of mammary tumours and lung adenomas in mice on VDC treatment still remains open and needs further clarification.
- (5) In our experiments we did not observe liver angiosarcomas, either in treated rats or in mice. The animals used were of the same breed that is highly susceptible to induction of angiosarcomas by vinyl chloride.
- (6) Our results have failed to confirm Viola's preliminary findings, which suggested that VDC was causing reticulosarcomas in rats.
- (7) Under our experimental conditions, adenocarcinoma of kidney in mice was the only tumour specifically linked to VDC exposure.
- (8) As far as this effect was concerned, there was a strong host influence: mice were more susceptible than rats and hamsters, and male mice much more than female mice.
- (9) There was a clear cut direct relationship between the degree of susceptibility to acute toxic and carcinogenic effects in the different animals species and sexes studied.
- (10) As a result of in vivo and in vitro studies it is probable that VDC is metabolized into more reactive compounds responsible for the toxic, mutagenic and carcinogenic effects of the monomer. The rate at which the active metabolic compounds are formed and metabolized depends on the concentration of administered VDC and on the metabolic pathways in the tested animals, which appear to be strongly influenced by species and sex, as well as by other factors.

3-2-78

- (11) The mice used had the appropriate metabolic conditions for indicating the oncogenic potentiality of VDC.
- (12) From a scientific point of view, the results of the studies on toxic, mutagenic, and carcinogenic effects of VDC and on its metabolism represent an exceptional integration of experimental multidisciplinary information.
- (13) We think that further investigations are needed in biological, biochemical, epidemiological, and medical fields, in order to
 - (a) further investigate the roles of species, strain, and sex on the pathological effects of VDC;
 - (b) learn more about the metabolism, with particular regard to active metabolic compounds, and the biological factors influencing the metabolic pathways;
 - (c) collect all possible epidemiological and medical data on occupationally exposed groups, which together with experimental results will provide the background for risk assessment.

8

Summary

The present report deals with the results of a wide array of correlated and integrated experiments aimed at the study of the long-term effects of VDC, with particular regard to carcinogenicity. The monomer is employed in the production of polymers whose major use is in the manufacturing of flexible packaging for food.

CONFIDENTIAL

Subject to Protection in
Ross v. *Calcasieu Parish* 337
14th *Calcasieu Parish, Louisiana*
Calcasieu Parish, Louisiana

CMA 015661

The monomer was tested by inhalation, in Sprague-Dawley rats (200-150, 100, 50, 25, 10 ppm), Swiss mice (200, 100, 50, 25, 10 ppm), and Chinese hamsters (25 ppm), and by ingestion in rats (at the doses of 20, 10, 5, 0.5 mg/kg body weight, in olive oil, by stomach tube).

The treatment was carried out 4-5 times weekly, for 1 year, with the exception of the groups of mice, treated by inhalation, at 200, 100 and 50 ppm, in which it was withdrawn after a few days, because of the excessive acute toxicity. 25 ppm is therefore the highest tested dose, compatible with a long-term treatment, by inhalation in mice.

The most important result was onset of kidney adenocarcinomas in mice exposed by inhalation at 50 and 25 ppm. Male mice appeared to be more susceptible than females. This tumour was not observed in mice exposed by inhalation at 10 ppm VDC or in the other treated animal species.

Increase of mammary tumours in rats and mammary tumours and lung adenomas in mice were found following inhalatory exposure to VDC. The lack of dose/ response relationship, the results of statistical analysis, and biological information from these as well as from other correlated experiments leave the problem of the correlation between these tumours and inhalation exposure to VDC or other monomers still open.

The available data based upon the studies performed in our and other laboratories show good correlation among the results of studies on carcinogenicity, toxicity, mutagenicity, and metabolism of VDC.

On the basis of our present knowledge on VDC toxicity and carcinogenicity, the need for further experimental and

CONFIDENTIAL

Subject: Order in
Ross v. No. 00-4837
14th Court
Calcasieu Parish, Louisiana

CMA 015662

epidemiological investigations for risk assessment has been suggested.

9 References

Balmer, M.F., Ramply, L.W., & Quast, J.F. (1975).
Dow Chemical Co., unpublished data.

Bartsch, H., Malaveille, C., Montesano, R., & Tomatis L. (1975).
Tissue-mediated mutagenicity in vinylidene chloride and
2-chlorobutadiene in Salmonella thyphimurium. Nature, 225,
641-643.

BASF (1976). Unpublished results.

Greim, H., Bonse, G., Radwan, Z., Reichert, D., & Henschler,
D. (1975). Mutagenicity in vitro and potential carcinogeni-
city of chlorinated ethylenes as a function of metabolic
oxirane formation. Biochemical Pharmacology, 24, 2013-2017.

Jaeger, R.J., Conolly, R.B., & Murphy, S.D. (1974).
Effect of 18th fast and glutathione depletion on 1,1-
-dichloroethylene-induced hepatotoxicity and lethality in
rats. Experimental Molecular Pathology, 20, 187-198.

Jaeger, R.J., Conolly, R.B., Reynolds, E.S., & Sheldon D. (1975).
Biochemical toxicology of unsaturated halogenated monomers.
Environmental Health Perspectives, 11, 121-128.

Jaeger, R.J., Shoner, L.G., & Coffman, L. (1977).
1,1-Dichloroethylene hepatotoxicity: proposed mechanism
of action and distribution and binding of ¹⁴C radio-
activity following inhalation exposure in rats.
Environmental Health Perspectives, 21, 113-119.

CONFIDENTIAL
Subject: ... in
Ross v. ... 4337
14th ...
Calcasieu Parish, Louisiana

CMA 015663

Jaeger, R.J., Trabulus, M.J., & Murphy, S.D. (1972). Vinylidene chloride hepatotoxicity and dissociation from a liperoxidative mechanism. Toxicology and Applied Pharmacology, 22, 310.

Jaeger, F.J., Trabulus, M.J., & Murphy, S.D. (1973). Biochemical effects of 1,1-dichloroethylene in rats: dissociation of its hepatotoxicity from a lipoperoxidative mechanism. Toxicology and Applied Pharmacology, 24, 457-467.

Jenkins, L.H., Trabulus, M.J., & Murphy, S.D. (1972). Biochemical effects of 1,1-dichloroethylene in rats: comparison with carbon tetrachloride and 1,1-dichloroethylene. Toxicology and Applied Pharmacology, 23, 501-510.

Lee, C.C., Bhandari, J.C., Winston, J.M., House, W.B., Dixon, R.L., & Woods, J.S. (1978). Carcinogenicity of vinyl chloride and vinylidene chloride. Journal of Toxicology and Environmental Health, 4, 15-30.

Lee, C.C., Bhandari, J.C., Winston, J.M., House, W.B., Peters, P.J., Dixon, R.L., & Woods, J.S. (1977). Inhalation toxicity of vinyl chloride and vinylidene chloride. Environmental Health Perspectives, 21, 25-32.

Maltoni, C. (1977 b). Recent findings on the carcinogenicity of chlorinated olefins. Environmental Health Perspectives, 21, 1-5.

Maltoni, C., Cotti, G., & Chieco, P. (1975). Tossicità acuta da cloruro di vinilidene: l'effetto della specie e del sesso. Gli Ospedali della Vita, 2/6, 105-106.

CONFIDENTIAL

Subject to Protective Order in
Ross v. ~~_____~~, No. 60-4837
14th Judicial District Court
Calcasieu Parish, Louisiana

CMA 015664

Maltoni, C., Cotti, G., Morisi, L. & Chieco, P. (1977 a). Carcinogenicity bioassays of vinylidene chloride (research plan and early results). La Medicina del Lavoro, 68, 241-262.

Maltoni, G., Patella, V., & Maioli, P. (In press). Toxicity and carcinogenicity bioassays of vinylidene chloride: acute toxicity.

McKenna, K.J., Watanabe, P.G., & Gehring, P.J. (1977). Pharmacokinetics of vinylidene chloride in rats. Environmental Health Perspectives, 21, 99-105.

Norris, J.M. (1977). Investigation of the potential toxicological effects and pharmacokinetics of inhaled and ingested vinylidene chloride in laboratory animals (MCA-Toxicology Programme for vinylidene chloride). Paper presented at European TAPPI Meeting, Hamburg.

Oesch, F., & Glatt, H.R. (1976). Screening tests in chemical carcinogenesis. IARC Scientific Publications, 12, 255-274.

Ott, M.G., Fishbeck, W.A., Townsend, J.C., & Scheider, E.J. (1976). A health study of employees exposed to vinylidene chloride. Journal of Occupation Medicine, 18, 735-738.

Rampy, L.W., Quast, J.F., Humiston, C.G., Balmer, M.F., & Schwetz, B.A. (1977). Interim results of two-year toxicological studies in rats of vinylidene chloride incorporated in the drinking water or administered by repeated inhalation. Environmental Health Perspectives, 21, 33-43.

Viola, P.L. (1974). Communication at the XI International Cancer Congress, Florence. Unpublished data.

CONFIDENTIAL

Subject to Protective Order in
Ross v. Conoco, Inc., No. 90-4837
14th Judicial District Court
Calcasieu Parish, Louisiana

CMA 015665


Viola, P.L., & Caputo, A. (1977). Carcinogenicity studies on vinylidene chloride. Environmental Health Perspectives, 21, 45-47.

CONFIDENTIAL
Subject to Protective Order in
Ross v. General Electric, No. 90-4837
14th J. ...
Calcasieu Parish, Louisiana

CMA 015666

TABLE 1

Experiment 81401 : Exposure by inhalation to Vinylidene Chloride (VDC)
in air at 150, 100, 50, 25, 10 ppm, 4 hours daily,
4-5 days weekly, for 52 weeks.



GROUPS NO.	CONCENTRATION	ANIMALS (Sprague-Dawley rats, 16 weeks old at start)		
		♂	♀	Total
I	200 (a) - 150 ppm	60	60	120
II	100 ppm	30	30	60
III	50 ppm	30	30	60
IV	25 ppm	30	30	60
V	10 ppm	30	30	60
VI	No treatment (Controls)	100	100	200
Total		280	280	560

(a) Two treatments only because of the high toxicity of this dose level.

CONFIDENTIAL

Subject to Protective Order in
Ross v. Central Board of Secondary Education
14th Judicial District Court
Calcasieu Parish, Louisiana

CMA 015667

July 78

DRAFT

TABLE 2



Experiment BT402 : Exposure by inhalation to Vinylidene Chloride (VDC)
in air at 200, 100, 50, 25, 10 ppm, 4 hours daily,
4-5 days weekly, for 52 weeks.

GROUPS - NO.	TREATMENT		ANIMALS (Swiss mice 16 weeks old (group I, II, III, IV, V, VI) and 9 weeks old (group IV bis and VII))		
	Concentration	Length	♂	♀	Total
I	200 ppm	2 days (d)	50	60	110
II	100 ppm	2 days (d)	30	30	60
III	50 ppm	1 weeks (d)	30	30	60
IV	25 ppm	52 weeks	30	30	60
IV bis (a)	25 ppm	52 weeks	120	120	240
V	10 ppm	52 weeks	30	30	60
VI	No treatment (Controls)(b)		100	100	200
VII	No treatment (Controls)(c)		90	90	180
Total			490	490	980

- (a) The treatment started two weeks later than in other groups.
(b) Controls to the groups I, II, III, IV, V.
(c) Controls to the group IV bis.
(d) The treatment was interrupted because of the high toxic effects and high mortality.

CONFIDENTIAL

Subject to Protective Order in
Ross v. General Electric Co. No. 80-4337
14th Floor, Court of Appeals
Calcutta, India

CMA 015668

TABLE 3

Experiment BT403 : Exposure by ingestion (stomach tube) to Vinylidene Chloride (VDC) in olive oil at 20, 10, 5 mg/Kg body weight, once daily, 4-5 days weekly, for 52 weeks.



GROUPS NO.	CONCENTRATION	ANIMALS (Sprague-Dawley rats, 9 weeks old at start)		
		♂	♀	Total
I	20 mg/Kg	50	50	100
II	10 mg/Kg	50	50	100
III	5 mg/Kg	50	50	100
IV	None (olive oil alone) (Controls)	100	100	200
Total		250	250	500

CONFIDENTIAL

Subject to Protective Order in
Recess v. Jorjoo, No. 80-1937
14th Judicial District Court
Calcasieu Parish, Louisiana

CMA 015669

TABLE 4

Stampa di un francobollo con il logo della Società Anonima di Assicurazioni e la scritta "BOLCINA".

Experiment BT404 : Exposure by ingestion (stomach tube) to Vinylidene Chloride (VDC) in olive oil at 0.5 mg/Kg body weight, once daily, 4-5 days weekly, for 52 weeks.


GROUPS NO.	CONCENTRATION	ASTHMAS (Sprague-Dawley rats, 10 weeks old at start)		
		♂	♀	Total
I	0.5 mg/Kg	50	50	100
II	None (olive oil alone) (Controls)	92	77	159
Total		132	127	259

CONFIDENTIAL

Subject to Probation
Ross v. Carson, 1957
14th Judicial District
Calcasieu Parish, Louisiana

CMA 015670

TABLE 5



Experiment 9T405 : Exposure by inhalation to Vinylidene Chloride (VDC)
in air at 25 ppm, 4 hours daily, 4-5 days weekly,
for 52 weeks.

GROUPS NO.	CONCENTRATION	ANIMALS (Chinese hamsters, 28 weeks old at start)		
		♂	♀	Total
I	25 ppm	30	30	60
II	No treatment (Controls)	18	17	35
Total		48	47	95

CONFIDENTIAL

Subject to 21 CFR 101.11
Ross V. Conner, M.D., M.P.H., M.Sc.
14th Floor, Room 1400
Calcasieu Parish, Louisiana

CMA 015671

TABLE 6

Experiment BT402 : Exposure by inhalation to Vinylidene Chloride (VDC), in air at
25, 10 ppm., 4 hours daily, 4-5 days weekly, for 52 weeks.
Results after 121 weeks (end of experiment).

NON NEOPLASTIC LESIONS OF LIVER

GROUPS No.	TREATMENT		ANIMALS (Swiss mice 16 wks old (Grp IV, V, VI) and 9 wks (IVbis) at start		ANIMALS WITH NON NEOPLASTIC LESIONS OF LIVER									
	Concentration	Length	Sex	No. at start	Examined animals		Regressive changes		Amyloidosis					
					No.	%	No.	%	Total		+ (±)		++ (±)	
									No.	%	No.	%	No.	%
IV	25 ppm.	52 weeks	♂	30	28	93.3	0	-	8	26.6	8	26.6	0	-
			♀	30	30	100.0	2	6.7	3	10.0	3	10.0	0	-
			♂ & ♀	60	58	96.7	2	3.3	11	19.0	11	19.0	0	-
IV bis	25 ppm.	52 weeks	♂	120	107	89.2	7	6.5	27	25.2	22	20.6	5	1.5
			♀	120	111	92.5	9	8.1	39	35.1	27	24.3	12	10.8
			♂ & ♀	240	218	90.8	16	7.3	66	30.3	49	22.5	17	7.9
V	10 ppm.	52 weeks	♂	30	26	86.7	0	-	7	26.9	6	23.1	1	3.6
			♀	30	27	90.0	3	11.1	6	22.2	4	14.8	2	7.4
			♂ & ♀	60	53	88.3	3	5.7	13	24.5	10	18.9	3	5.7
VI	No treatment (controls)		♂	100	85	85.0	5	5.9	73	85.9	11	12.9	62	72.9
			♀	100	91	91.0	3	3.3	63	69.2	18	19.6	45	49.4
			♂ & ♀	200	176	88.0	8	4.5	136	71.3	29	16.5	107	60.6
Total				560	505									

CMA 015672

COPIED FROM
Subject to the provisions of
Ross v. Crompton, 1937, 4837
14th Dec 1937
Calcutta Municipal Corporation

TABLE 7.

Experiment BT402 : *Xenopus* by inhalation to Vinylidene Chloride (VDC) in air at 200, 100, 50, 25, 10 ppm, 4 hours daily, 4-5 days weekly, for 52 weeks. Results after 121 weeks (end of experiment).


NON NEOPLASTIC LESIONS OF KIDNEY

GROUPS NO.	TREATMENT		ANIMALS (Swiss mice 16 wks old (Grp I, II, III, IV, V, VI) and 9 wks old (Grp IV bis, VII) at start)		ANIMALS WITH NON NEOPLASTIC LESIONS OF KIDNEY															
					Examined animals		Regressive changes		Amyloidosis						Chronic nephritis					
	Concentration	Length	Sex	No. at start	No.	%	No.	%	Total		+ (c)		++ (a)		Total		+ (a)		++ (a)	
IV	25 ppm	52 weeks	♂	30	28	93.3	0	-	25	89.3	12	42.6	13	46.4	18	64.3	5	17.9	13	46.4
			♀	30	30	100.0	1	3.3	24	80.0	12	40.0	12	40.0	19	63.3	2	6.7	10	33.3
			♂ and ♀	60	58	96.7	1	1.7	49	81.7	24	41.4	25	41.7	37	61.7	7	11.7	23	38.3
IV bis	25 ppm	52 weeks	♂	120	110	91.7	0	-	70	70.9	43	39.1	35	31.8	63	52.5	21	17.5	42	35.0
			♀	120	112	93.3	0	-	77	68.7	12	10.7	65	58.0	59	52.7	19	17.0	40	35.7
			♂ and ♀	240	222	92.5	0	-	155	69.8	55	24.8	100	45.0	122	54.9	40	18.0	82	36.9
V	10 ppm	52 weeks	♂	30	23	76.7	0	-	21	91.3	11	47.9	10	43.5	17	73.9	4	17.4	13	56.5
			♀	30	25	83.3	0	-	19	76.0	4	16.0	15	60.0	11	44.0	3	12.0	8	32.0
			♂ and ♀	60	48	80.0	0	-	40	81.3	15	31.2	25	52.1	28	58.3	7	14.6	21	43.8
VI	No treatment (Controls)		♂	100	82	82.0	0	-	59	71.9	22	26.3	37	45.1	57	69.5	20	24.4	37	45.1
			♀	100	89	89.0	0	-	59	66.3	22	24.7	37	41.6	61	68.5	24	27.0	37	41.6
			♂ and ♀	200	171	85.5	0	-	118	69.0	44	25.7	74	43.3	118	69.0	44	25.7	74	43.3
VII	No treatment (Controls)		♂	90	61	67.8	0	-	44	58.3	29	35.3	15	18.5	49	59.2	34	37.8	14	17.3
			♀	90	63	70.0	0	-	38	52.7	15	20.0	13	17.3	35	47.9	15	20.0	7	9.3
			♂ and ♀	180	124	68.9	0	-	82	55.5	44	27.7	28	17.7	84	50.7	49	26.8	21	14.6
Total				980																

(a) + : mild; ++ : marked.

CMA 015673

CONVULSIONS
 Subj. V. No. 1000
 1957
 14th
 Calcutta, India, Louisiana



Experiment BT401: Exposure by inhalation to Vinylidene Chloride (VDC) in air at 150, 100, 50, 25, 10 ppm, 4 hours daily, 4-5 days weekly, for 52 weeks.
Results after 137 weeks (end of experiment).

DISTRIBUTION OF THE DIFFERENT TYPES OF TUMOURS

GROUP NO.	CONCENTRATION	ANIMALS (Sprague-Dawley rats, 16 weeks old at start)			ANIMALS WITH TUMOURS												Total (f)		
		Sex	No. at start	Corrected number (a)	Mammary tumours (b)			Zymbal gland carcinomas			Leukaemias			Other tumours			Total		Average difference tumours/animal (g)
					Total No.	% (c)	Average latency time (weeks) (d)	Total No.	% (e)	Average latency time (weeks) (f)	Total No.	% (c)	Average latency time (weeks) (g)	Total No.	Benign No.	Malignant No.	No.	% (c)	
I	150 ppm	♂	60	60	11	18.3	97 ± 14	0	—	—	1	5.0	90 ± 9	7	5	2	14	23.3	1.2
		♀	60	60	44	73.3	82 ± 1	0	—	—	3	5.0	71 ± 33	6	1	5	47	78.3	1.1
		♂ and ♀	120	120	55	45.8	89 ± 3	0	—	—	4	5.0	81 ± 18	13	6	7	62	51.7	1.1
		♂	30	30	5	16.7	106 ± 9	0	—	—	2	6.6	79 ± 4	5	0	2	11	36.7	1.4
II	100 ppm	♀	30	32	25	78.1	82 ± 4	1	3.3	54	1	3.3	115	4	2	2	27	83.3	1.1
		♂ and ♀	60	62	30	48.4	94 ± 3	1	1.7	54	3	5.0	93 ± 25	9	2	1	30	48.4	1.3
		♂	30	33	7	21.2	105 ± 5	1	3.3	50	0	—	—	7	3	2	11	33.3	1.1
		♀	30	30	23	76.7	79 ± 4	0	—	—	0	—	—	4	2	2	24	80.0	1.1
III	50 ppm	♂ and ♀	60	60	30	50.0	86 ± 4	1	1.7	50	0	—	—	11	7	4	25	41.7	1.2
		♂	30	28	4	13.3	101 ± 10	0	—	—	3	—	—	—	—	—	3	10.0	1.1
		♀	30	30	27	90.0	80 ± 4	1	3.3	74	0	—	—	1	1	0	28	93.3	1.1
		♂ and ♀	60	58	25	43.1	88 ± 6	1	1.7	74	0	—	—	2	4	0	31	53.4	1.1
IV	25 ppm	♂	30	29	3	10.3	81 ± 23	0	—	—	3	10.3	73 ± 14	2	—	2	6	20.0	1.1
		♀	30	30	26	86.7	81 ± 4	0	—	—	0	—	—	4	1	1	27	90.0	1.1
		♂ and ♀	60	59	31	52.5	81 ± 4	0	—	—	3	5.1	73 ± 15	6	1	3	33	55.0	1.1
		♂	30	29	3	10.0	81 ± 23	0	—	—	3	10.0	73 ± 14	2	—	2	6	20.0	1.1
V	10 ppm	♂	30	29	3	10.3	81 ± 23	0	—	—	3	10.3	73 ± 14	2	—	2	6	20.0	1.1
		♀	30	30	26	86.7	81 ± 4	0	—	—	0	—	—	4	1	1	27	90.0	1.1
		♂ and ♀	60	59	31	52.5	81 ± 4	0	—	—	3	5.1	73 ± 15	6	1	3	33	55.0	1.1
		♂	30	29	3	10.3	81 ± 23	0	—	—	3	10.3	73 ± 14	2	—	2	6	20.0	1.1
VI	No treatment (controls)	♂	100	97	11	12.6	115 ± 6	1	1.4	82	3	3.1	69 ± 16	13	5	8	21	21.6	1.2
		♀	100	99	61	61.6	37 ± 2	0	—	—	4	4.0	90 ± 9	7	3	4	52	52.5	1.1
		♂ and ♀	200	196	72	36.7	91 ± 3	1	0.5	82	7	3.8	86 ± 9	20	8	12	73	36.7	1.1
		Total			560	543													

(a) Alive animals after 10 weeks, when the first tumour (a leukaemia) was observed.

(b) Two or more tumours of the same and/or different types (fibroadenomas, carcinomas, sarcomas, carcinosarcomas) may be present in the same animal.

(c) The percentages are referred to the corrected number.

(d) Average age at the onset of the first mammary tumour per animal, detected at the periodic control or at autopsy.

(e) Average time from the start of the experiment to the detection (at the periodic control or at autopsy).

(f) Several animals with two or more tumours.

Subject
Ross V
14th Judicial District Court
Calcasieu Parish, Louisiana

CMA 015674

Experiment BMD-1 : Exposure by Inhalation to Vinylidene Chloride (VDC) in air at 150, 100, 50, 25, 10 ppm, 4 hours daily, 4-5 days weekly, for 92 weeks.
Results after 137 weeks (end of the experiment).



DISTRIBUTION OF THE DIFFERENT TYPES OF TUMORS (OTHER) TREATED


GROUPS NO.	SEX	ANIMALS SHOWING OTHER TUMORS			
		Benign		Malignant	
		No.	Distribution of histotypes	No.	Distribution of histotypes
I	♂	5	1 Zymbal gland adenoma 3 dermatofibromas 1 adrenal pheochromocytoma	2	1 subcutaneous sarcoma 1 peritoneal mesothelioma
	♀	1	1 Zymbal gland adenoma	5	1 intestinal adenocarcinoma 1 ovary fibrosarcoma 1 carcinoma of the uterus 1 intraabdominal sarcoma 1 lymphnode angiosarcoma
II	♂	6	3 dermatofibromas 1 forestomach papilloma 1 Leydig cells tumor 1 lymphnode angiosarcoma	2	1 subcutaneous sarcoma 1 pancreas adenocarcinoma
	♀	2	1 adrenal cortical adenoma 1 urinary bladder papilloma	2	1 intraabdominal sarcoma 1 carcinoma of the uterus
III	♂	5	1 subcutaneous lipoma 1 intraabdominal lipoma 1 forestomach papilloma 1 spleen angiosarcoma 1 urinary bladder papilloma	2	1 skin carcinoma 1 intraabdominal liposarcoma
	♀	2	1 Zymbal gland adenoma 1 adrenal pheochromocytoma	2	1 ovary arrhenoblastoma 1 carcinoma of the uterus
IV	♂	4	2 dermatofibromas 1 subcutaneous lipoma 1 Leydig cells tumor	0	
	♀	1	1 forestomach papilloma	0	
V	♂	0		2	1 subcutaneous sarcoma 1 adrenal pheochromoblastoma
	♀	1	1 subcutaneous lipoma	3	1 subcutaneous sarcoma 1 intraabdominal sarcoma 1 leiomyosarcoma of the uterus
VI	♂	5	1 dermatofibroma 1 subcutaneous lipoma 1 subcutaneous fibrosarcoma 1 forestomach papilloma 1 adrenal cortical adenoma	5	2 subcutaneous sarcomas 1 ovary gland carcinoma 1 ovary adenocarcinoma 1 intraabdominal sarcoma 1 adrenal pheochromoblastoma 1 testicular mesothelioma 1 malignant neoplasm
	♀	3	1 Zymbal gland adenoma 1 subcutaneous lipoma 1 adrenal cortical adenoma	4	1 adrenal cortical carcinoma 3 carcinomas of the uterus

Subject to
Foss v. CMA
14th July
Calcasieu Parish, Louisiana

Draft

TABLE 10

Experiment BT401 : Exposure by Inhalation to Vinylidene Chloride (VDC) in air at 150, 100, 50, 25, 10 ppm, 4 hours daily, 4-5 days weekly, for 52 weeks. Results after 137 weeks (end of the experiment)



INCIDENCE OF PITUITARY ADENOMATOUS GROWTH

GROUPS NO.	CONCENTRATION	ANIMALS (Sprague-Dawley rats, 10 weeks old at start)			PITUITARY ADENOMATOUS GROWTH	
		Sex	No. at start	Corrected number (a)	No.	%
I	150 ppm	♂	60	60	3	5.0
		♀	60	60	7	11.7
		♂ and ♀	120	120	10	8.3
II	100 ppm	♂	30	30	3	10.0
		♀	30	30	1	3.3
		♂ and ♀	60	60	4	6.7
III	50 ppm	♂	30	30	3	10.0
		♀	30	30	2	6.7
		♂ and ♀	60	60	5	8.3
IV	25 ppm	♂	30	28	1	3.6
		♀	30	30	1	3.3
		♂ and ♀	60	58	2	3.4
V	10 ppm	♂	30	29	1	3.4
		♀	30	30	0	-
		♂ and ♀	60	59	1	1.7
VI	No treatment (Controls)	♂	100	87	2	2.3
		♀	100	99	11	11.1
		♂ and ♀	200	186	13	7.0

(a) Alive animals at 10 weeks, when the first tumour (a leukaemia) was observed.

Subject to Project 137
 Ross v. ...
 14th ...
 Calcasieu Parish, Louisiana

CMA 015676

Experiment BT401 : Exposure by inhalation to Vinylidene Chloride (VDC) in air at 150, 100, 50, 25, 10 ppm, 4 hours daily, 4-5 days weekly, for 52 weeks.
Results after 137 weeks (end of experiment).

DISTRIBUTION OF THE DIFFERENT TYPES OF MAMMARY TUMOURS

GROUP NO.	CONCENTRATION	ANIMALS (Sprague-Dawley rats, 16 weeks old at start)			MAMMARY TUMOURS (b)																		
		Sex	No. at start	Corrected number (c)	Total No.	%	Average latency time (weeks) (d)	No. of tumours/tumours bearing animals	Total No.	%	(e)	Histologically examined											
												Histotype											
												Fibromas and fibroadenomas			Carcinomas			Sarcomas			Carcinosarcomas		
No.	% (f)	Average latency time (weeks) (g)	No.	% (f)	Average latency time (weeks) (h)	No.	% (f)	Average latency time (weeks) (i)	No.	% (f)	Average latency time (weeks) (j)												
I	150 ppm	♂	60	60	3	13.3	97±14	1.0	8	100.0	6	75.0	109±8	1	12.5	26	0	-	-	1	12.5	76	
		♀	60	60	14	73.3	82±3	1.5	43	97.7	33	88.4	83±3	9	20.9	78±8	0	-	-	0	-	-	
		♂ and ♀	120	120	52	43.3	82±3	1.4	51	98.1	44	86.3	76±3	10	19.6	73±8	0	-	-	1	2.0	75	
II	100 ppm	♂	30	30	5	16.7	104±9	1.0	5	100.0	5	100.0	104±9	0	-	-	0	-	-	0	-	-	
		♀	30	30	25	83.3	82±4	1.7	23	92.0	21	91.3	83±5	3	13.0	102±10	0	-	-	0	-	-	
		♂ and ♀	60	60	30	50.0	85±4	1.6	28	93.3	26	92.8	87±4	3	10.7	102±10	0	-	-	0	-	-	
III	50 ppm	♂	30	30	7	23.3	106±5	1.0	7	100.0	7	100.0	106±5	0	-	-	0	-	-	0	-	-	
		♀	30	30	21	76.7	79±4	1.9	22	95.6	21	95.4	82±4	1	4.5	68	0	-	-	0	-	-	
		♂ and ♀	60	60	28	46.7	86±4	1.7	29	96.7	28	96.3	80±4	1	3.4	68	0	-	-	0	-	-	
IV	25 ppm	♂	30	29	4	14.3	103±10	1.0	4	100.0	4	100.0	103±10	0	-	-	0	-	-	0	-	-	
		♀	30	30	21	70.0	86±4	1.6	20	95.2	20	100.0	87±4	4	20.0	82±10	0	-	-	0	-	-	
		♂ and ♀	60	59	25	43.3	88±4	1.5	24	96.0	24	100.0	90±4	4	16.7	82±10	0	-	-	0	-	-	
V	10 ppm	♂	30	29	3	10.3	81±23	1.0	3	100.0	3	100.0	81±23	0	-	-	0	-	-	0	-	-	
		♀	30	30	28	93.3	83±4	1.6	24	85.7	24	100.0	85±4	5	20.8	90±14	0	-	-	0	-	-	
		♂ and ♀	60	59	31	52.5	81±4	1.5	27	87.1	27	100.0	85±4	5	18.5	90±14	0	-	-	0	-	-	
VI	No treatment (Controls)	♂	100	87	11	12.6	115±6	1.0	11	100.0	11	100.0	115±6	0	-	-	0	-	-	0	-	-	
		♀	100	99	61	61.6	87±2	1.5	56	91.8	44	78.6	88±3	16	28.6	95±5	0	-	-	0	-	-	
		♂ and ♀	200	186	72	38.7	91±3	1.4	67	93.0	55	82.1	93±3	16	23.9	95±5	0	-	-	0	-	-	
Total			560	543																			

(a) Alive animals after 10 weeks, when the first tumour (a leukaemia) was observed.

(b) Two or more tumours of the same and/or different types (fibroadenomas, carcinomas, sarcomas, carcinosarcomas) may be present in the same animal.

(c) The percentages are referred to the corrected number.

(d) Average age at the onset of the first mammary tumour per animal, detected at the periodic control or at autopsy.

(e) The percentages are referred to total number of animals bearing mammary tumours.

(f) The percentages are referred to total number of animals bearing mammary tumours, histologically examined.

CMA 015677

Subject: Ross V. ...
14th Jan 1977
California Institute, Louisiana
337

TABLE 12

Experiment BT401 : Exposure by inhalation to Vinylidene Chloride (VDC) in air at 150, 100, 50, 25, 10 ppm, 4 hours daily, 4-5 days weekly, for 52 weeks. Results after 137 weeks (end of the experiment).

BIOLOGICAL PARAMETERS RELATED TO MAMMARY TUMOURS

EXPOSURE CONCENTRATION (ppm)	ANIMALS (Sprague-Dawley rats, females, 16 weeks old at start)						AVERAGE AGE AT THE ONSET OF THE TUMOUR					MEAN WEIGHT (g)						AVERAGE AGE AT DEATH		HISTOLOGY OF MAMMARY & DISSECTION AND GROSS EXAMINATIONS FEMALE RATS WITH OR WITHOUT MAMMARY TUMOURS					
	No. at start	Corrected No. (a)	Animals with tumours		Animals without tumours		Total	Fibroadenomas	Carcinomas	Sarcomas	Carcinomas not examined	4 months		6 months		12 months		Animals with tumours	Animals without tumours	Animals with mammary tumours		Animals with mammary tumours			
			No.	%	No.	%						Animals with tumours	Animals without tumours	Animals with tumours	Animals without tumours	Animals with tumours	Animals without tumours			Animals with tumours	Animals without tumours	No.	%	No.	%
150 ppm	60	60	7	11.7	16	26.7	82 ± 3	83 ± 3	78 ± 4	-	-	256	267	324	329	350	355	102 ± 3	90 ± 7	5	4.9	1	1.1		
100 ppm	60	60	15	25.0	5	8.3	82 ± 4	83 ± 5	102 ± 10	-	-	283	263	331	302	359	328	102 ± 4	90 ± 6	1	4.0	0	-		
50 ppm	60	60	7	11.7	7	11.7	80 ± 4	81 ± 4	80	-	-	275	280	324	328	361	334	105 ± 4	91 ± 7	1	4.8	1	1.1		
25 ppm	60	60	21	35.0	9	15.0	86 ± 4	87 ± 4	82 ± 10	-	-	279	275	330	336	379	380	105 ± 4	91 ± 11	1	4.8	0	-		
10 ppm	60	60	1	1.7	2	3.3	81 ± 4	82 ± 4	90 ± 14	-	-	263	275	318	335	352	357	105 ± 4	90 ± 13	1	-	1	-		
Control (Cage-mates)	60	59	6	10.2	38	64.4	87 ± 2	88 ± 3	95 ± 5	-	-	268	274	321	335	373	364	107 ± 2	78 ± 5	8	13.6	0	-		

(a) Five animals after 10 weeks, when the first tumour (a leukemia) was observed.

Insert

CMA 015678

CONFIDENTIAL
Subject to review and release in
accordance with the provisions of
the Freedom of Information Act
14th
Revised Edition
Copyright 1987

CMA 015679

15

[illegible]

- (a) Alive animals after 14 weeks, when the first tumour (r mammary carcinoma) was observed.
- (b) Two or more tumours of the same and/or different types (fibroadenomas, carcinomas, sarcomas, carcinosarcomas) may be present in the same animal.
- (c) The percentages are referred to the corrected number.
- (d) Average age at the onset of the first mammary tumour per animal, detected at the periodic control or at autopsy.
- (e) Average time from the start of the experiment to the detection (at the periodic control or at autopsy).
- (f) Several animals with two or more tumours.

CONFIDENTIAL

Draft

TABLE 14

Experiment BT-03 : Exposure by ingestion (stomach tube) to Vinylidene Chloride (VDC) in olive oil at 20, 10, 5 mg/Kg body weight, once daily, 4-5 days weekly, for 52 weeks.
Results after 147 weeks (end of the experiment).



DISTRIBUTION OF THE DIFFERENT TYPES OF MISCELLANEOUS ("OTHER") TUMOURS

GROUPS NO.	SEX	ANIMALS BEARING OTHER TUMOURS				
		Benign		Malignant		Total
		No.	Distribution of histotypes	No.	Distribution of histotypes	
I	♂	2	1 skin acanthoma 1 dermatofibroma	2	1 subcutaneous sarcoma 1 intestinal adenocarcinoma	4
	♀	3	3 forestomach papillomas	2	1 ovary carcinoma 1 carcinoma of the uterus	5
II	♂	2	3 dermatofibromas	4	4 subcutaneous sarcomas	7
	♀	2	1 hepatoma 1 adrenal cortical adenomas	3	1 intrabdominal sarcoma 1 adenocarcinoma of the uterus 1 pericytosarcoma of a lymphnode	5
III	♂	2	2 dermatofibromas	1	1 thymus pericytosarcoma	3
	♀	1	1 adrenal cortical adenoma	4	2 subcutaneous sarcomas 1 adrenal cortical carcinoma 1 adenocarcinoma of the uterus	5
IV	♂	7	1 skin sebaceous adenoma 2 dermatofibromas 1 subcutaneous lipoma 2 forestomach papillomas 1 Leydig cells tumour	3	3 subcutaneous sarcomas	10
	♀	8	1 Zymbal gland acanthoma 1 intrabdominal lipoma 1 hepatoma 1 forestomach papilloma 1 adrenal cortical adenoma 1 adrenal pheochromocytoma 1 adrenal gland ganglioneuroma 1 leiomyosarcoma of the uterus	5	1 liver angiosarcoma 1 adrenal pheochromoblastoma 1 ovary carcinoma 2 adenocarcinomas of the uterus	13

CONFIDENTIAL

Subject to review by the
Ross v. ...
14th ...
Calculated ...

CMA 015680

TABLE 15

Experiment BT403 : Exposure by ingestion (stomach tube) to Vinylidene Chloride (VDC) in olive oil at 20, 10, 5 mg/Kg body weight, once daily, 4-5 days weekly, for 52 weeks.
Results after 147 weeks (end of the experiment).

INCIDENCE OF PITUITARY ADENOMATOUS GROWTH

GROUPS NO.	CONCENTRATION	ANIMALS (Sprague-Dawley rats, 9 weeks old at start)			PITUITARY ADENOMATOUS GROWTH	
		Sex	No. at start	Corrected number (a)	No.	%
I	20 mg/Kg	♂	50	49	2	4.1
		♀	50	48	5	10.4
		♂ and ♀	100	97	7	7.2
II	10 mg/Kg	♂	50	48	3	6.2
		♀	50	50	0	-
		♂ and ♀	100	98	3	3.1
III	5 mg/Kg	♂	50	49	1	2.0
		♀	50	50	7	14.0
		♂ and ♀	100	99	8	8.1
IV	Olive oil (Controls)	♂	100	100	4	4.0
		♀	100	99	9	9.1
		♂ and ♀	200	199	13	6.5

(a) Alive animals after 14 weeks, when the first tumour (a mammary carcinoma) was observed.



CONFIDENTIAL
Subject to Protection in
Ross v. Calcasieu
14th
Calcasieu Parish

CMA 015681

Experiment BT403 : Exposure by ingestion (stomach tube) to Vinylidene Chloride (VDC) in olive oil at 20, 10, 5 mg/Kg body weight, once daily, 4-5 days weekly, for 52 weeks. Results after 147 weeks (end of experiment).

DISTRIBUTION OF THE DIFFERENT TYPES OF MAMMARY TUMOURS

GROUP NO.	CONCENTRATION	ANIMALS (Sprague-Dawley rats, 9 weeks old at start)			MAMMARY TUMOURS (b)													
		Sex	No. at start	Corrected number (c)	Total No.	%	Average latency time (weeks) (d)	No. of tumours bearing animals	Total No.	%	Histologically examined							
											Histotype							
											Fibrosarcoma and fibroadenoma		Carcinoma		Sarcoma		Carcinosarcoma	
											Total No. (e)	Average latency time (weeks) (f)	Total No. (g)	Average latency time (weeks) (h)	Total No. (i)	Average latency time (weeks) (j)	Total No. (k)	Average latency time (weeks) (l)
I	20 mg/Kg	♂	20	19	2	4.7	112 ± 27	1.0	2	100.0	2	100.0	112 ± 27	0	-	-	0	-
		♀	50	48	23	47.9	71 ± 5	1.4	22	95.6	17	77.3	76 ± 6	7	31.8	42 ± 12	0	-
		♂ and ♀	70	67	25	35.8	74 ± 6	1.4	24	96.0	19	79.2	80 ± 6	7	29.2	42 ± 12	0	-
II	10 mg/Kg	♂	20	17	2	1.1	100 ± 0	1.0	2	100.0	2	100.0	100 ± 0	0	-	-	0	-
		♀	50	48	24	50.0	57 ± 3	1.4	26	100.0	20	76.9	93 ± 5	7	26.9	78 ± 7	0	-
		♂ and ♀	70	65	26	26.5	67 ± 4	1.4	26	100.0	22	84.6	92 ± 5	7	26.9	78 ± 7	0	-
III	5 mg/Kg	♂	20	17	2	1.1	95 ± 5	1.0	2	100.0	2	100.0	95 ± 5	0	-	-	0	-
		♀	50	47	23	50.0	50 ± 4	1.5	28	100.0	23	82.9	88 ± 4	3	10.7	95 ± 10	1 (p. 3.0)	-
		♂ and ♀	70	64	25	30.3	91 ± 3	1.5	30	100.0	25	83.3	89 ± 3	3	10.0	95 ± 10	1 (p. 3.0)	-
IV	Olive oil (control)	♂	100	100	10	10.0	112 ± 3	1.0	10	100.0	10	100.0	112 ± 3	1	13.1	-	0	-
		♀	100	93	57	57.5	83 ± 3	1.4	57	100.0	42	73.7	85 ± 3	16	28.1	52 ± 6	2 (h) 3.5	1 1.7
		♂ and ♀	200	193	67	33.7	87 ± 3	1.3	67	100.0	52	77.6	90 ± 3	17	25.4	54 ± 6	2 3.0	1 1.5
Total			500	493														

(a) Alive animals after 14 weeks, when the first tumour (a mammary adenoma) was observed.

(b) Two or more tumours of the same and/or different types (fibroadenomas, carcinomas, sarcomas, carcinosarcomas) may be present in the same animal.

(c) The percentages are referred to the corrected number.

(d) Average age at the onset of the first mammary tumour per animal, detected at the periodic control or at autopsy.

(e) The percentages are referred to total number of animals bearing mammary tumours.

(f) The percentages are referred to total number of animals bearing mammary tumours, histologically examined.

(g) 1 fibrosarcoma.

(h) 1 fibrosarcoma; 1 pericytoma.

CMA 015682

Submitted to
Ross V
14th June 1971
Calcasieu Parish, Louisiana

TABLE 17

Experiment HT403 : Exposure by ingestion (stomach tube) to Vinylidene Chloride (VDC) in olive oil at 20, 10, 5 mg/kg body weight, once daily, 4-5 days weekly, for 52 weeks. Results after 147 weeks (end of the experiment).

BIOLOGICAL PARAMETERS RELATED TO MAMMARY TUMOURS

DOSE (mg/kg)	ANIMALS SURVIVING TO 14 WEEKS (9 WEEKS AFTER START)				PERCENTAGE ARE AT THE ONSET OF THE TUMOURS (Weeks)					MEAN WEIGHT (g)						ANIMALS WITH TUMOURS (Weeks)							
	No. at start	CORTAGE +1 No. (1)	Animals with tumours		Animals without tumours		Total	Fibro- aden- oma	Carcin- omas	Carcin- oma	Carcin- omas	4 months		6 months		12 months		Animals with tumours	Animals without tumours	Animals with tumours	Animals with tumours		
			No.	%	No.	%						Animals with tumours	Animals without tumours	Animals with tumours	Animals without tumours	Animals with tumours	Animals without tumours						
20 mg/kg	50	49	23	7.9	25	52.1	71 ± 6	76 ± 6	72 ± 12	-	-	258	256	312	303	375	344	95 ± 3	75 ± 5	3	100	2	100
10 mg/kg	50	50	24	48.0	25	52.0	87 ± 5	93 ± 5	78 ± 7	-	-	263	253	314	302	362	346	111 ± 5	73 ± 6	0	-	0	-
5 mg/kg	50	50	22	44.0	22	44.0	90 ± 4	38 ± 4	95 ± 10	128	-	258	257	301	296	338	341	110 ± 4	59 ± 5	5	17.5	2	5.0
Control (olive oil)	100	50	57	57.6	42	42.4	85 ± 3	65 ± 3	82 ± 6	87 ± 16	39	258	251	314	314	357	343	104 ± 3	80 ± 4	5	2.2	4	5.0

(a) Alive animals after 14 weeks, when the first tumour (a mammary sarcoma) was observed.

Draft

CMA 015683

CONFIDENTIAL
Subject to Protective Order in
Ross v. General Electric Co. No. 90-4837
JAN 11 1991
CALIFORNIA STATE ARCHIVES

Experiment BT404 : Exposure by ingestion (stomach tube) to Vinylidene Chloride (VDC) in olive oil at 0.5 mg/kg body weight, once daily, 4-5 days weekly, for 52 weeks.
Results after 136 weeks (end of experiment).

DISTRIBUTION OF THE DIFFERENT TYPES OF TUMOURS

GROUP NO.	CONCENTRATION	ANIMALS (Sprague-Dawley rats, 10 weeks old at start)			ANIMALS WITH TUMOURS														
		Sex	No. at start	Corrected number (a)	Mammary tumours (b)			Zymal gland carcinomas			Leukaemias			Other tumours			Total (f)		
					Total No.	% (c)	Average latency time (weeks) (d)	Total No.	% (e)	Average latency time (weeks) (e)	Total No.	% (f)	Average latency time (weeks) (g)	Total No.	Benign No.	Malignant No.	Total No.	% (h)	No. of animals with tumours (i)
I	0.5 mg/kg	♂	50	49	2	4.1	105±1	0	-	-	2	4.1	95±8	2	0	2	2	4.1	1.0
		♀	50	48	22	45.8	84±3	0	-	-	1	2.1	111	4	0	4	22	45.8	1.0
		♂ and ♀	100	97	24	24.7	86±4	0	-	-	3	3.1	100±7	6	0	6	26	26.9	1.2
II	Olive oil (Controls)	♂	82	81	0	2.5	75±13	0	-	-	4	4.9	58±15	1	1	0	1	1.2	1.1
		♀	77	77	34	44.2	83±3	1	1.3	90	2	2.6	82±20	4	1	3	38	49.3	1.1
		♂ and ♀	159	158	36	22.8	83±3	1	0.6	90	6	3.8	66±14	5	2	3	45	28.5	1.1
Total			259	255															

(a) Alive animals after 20 weeks, when the first tumour (a leukaemia) was observed.

(b) Two or more tumours of the same and/or different types (fibroadenomas, carcinomas, sarcomas, carcinosarcomas) may be present in the same animal.

(c) The percentages are referred to the corrected number.

(d) Average age at the onset of the first mammary tumour per animal, detected at the periodic control or at autopsy.

(e) Average time from the start of the experiment to the detection (at the periodic control or at autopsy).

(f) Several animals with two or more tumours.

Draft

CMA 015684

Submitted to the
 14th Judicial District
 Calcasieu Parish, Louisiana
 Ross V. [illegible]
 1957

TABLE 19

Experiment BT404 : Exposure by ingestion (stomach tube) to Vinylidene Chloride (VDC) in olive oil at 0.5 mg/Kg body weight, once daily, 4-5 days weekly, for 52 weeks.
Results after 136 weeks (end of the experiment).



DISTRIBUTION OF THE DIFFERENT TYPES OF MISCELLANEOUS ("OTHER") TUMOURS

GROUPS NO.	SEX	ANIMALS BEARING OTHER TUMOURS			
		Benign		Malignant	
		No.		No.	Total
I	♂	0		2	2
	♀	0		4	4
II	♂	1	1 adrenal cortical adenoma	0	1
	♀	1	1 forestomach papilloma	3	4
					1 kidney adenocarcinoma 1 adenocarcinoma of the uterus 1 fibrosarcoma of the uterus

Dr. J. J.

CMA 015685

CONFIDENTIAL
 Subject to Protective Order in
 Case No. 90-4837
 Filed in the Court
 California Parish, Louisiana

TABLE 20

Experiment BM04: Exposure by ingestion (stomach tube) to Vinylidene Chloride (VDC) in olive oil at 0.5 mg/Kg body weight, once daily, 4-5 days weekly, for 52 weeks.
Results after 136 weeks (end of the experiment)



INCIDENCE OF PITUITARY ADENOMATOUS GROWTH

GROUPS NO.	CONCENTRATION	ANIMALS (Sprague-Dawley rats, 10 weeks old at start)			PITUITARY / ADENOMATOUS GROWTH	
		Sex	No. at start	Corrected number (a)	No.	%
I	0.5 mg/Kg	♂	50	49	0	-
		♀	50	46	6	12.5
		♂ and ♀	100	97	6	6.1
II	Olive oil (Controls)	♂	82	81	0	-
		♀	77	77	2	2.6
		♂ and ♀	159	158	2	1.3

(a) Alive animals after 20 weeks, when the first tumour (a leukaemia) was observed.

CMA 015686

CONFIDENTIAL
Subj. to the order in
Ross 90-4837
14th Jan 1971
Calcutta Port 13

TABLE 21

Experiment BT404 : Exposure by ingestion (stomach tube) to Vinylidene Chloride (VDC) in olive oil at 0.5 mg/Kg body weight, once daily, 4-5 days weekly, for 52 weeks. Results after 136 weeks (end of experiment).

DISTRIBUTION OF THE DIFFERENT TYPES OF MAMMARY TUMOURS

EXP NO.	CONCENTRATION	ANIMALS (Sprague-Dawley rats, 10 weeks old at start)			MAMMARY TUMOURS (b)																	
		Sex	No. at start	Corrected number (a)	Total No.	%	Average latency time (weeks) (d)	No. of tumours bearing animals	Histologically examined													
									Total No.	%	Fibromas and fibroadenomas			Carcinomas			Sarcomas			Carcinosarcomas		
											No.	%	Average latency time (weeks) (d)	No.	%	Average latency time (weeks) (d)	No.	%	Average latency time (weeks) (d)	No.	%	Average latency time (weeks) (d)
1	0.5 mg/Kg	♂	50	43	2	4.1	105±41	1.0	2	100.0	2	100.0	105 ± 41	0	-	-	0	-	-	0	-	-
		♀	50	48	22	45.8	84 ± 3	1.3	22	100.0	21	95.4	84 ± 3	2	9.1	83 ± 1	0	-	-	0	-	-
		♂ and ♀	100	91	24	24.7	85 ± 4	1.3	24	100.0	23	94.5	84 ± 4	2	8.3	83 ± 1	0	-	-	0	-	-
23	Olive oil (controls)	♂	32	31	2	2.5	75±13	1.0	2	100.0	2	100.0	75 ± 13	0	-	-	0	-	-	0	-	-
		♀	77	77	34	44.2	95 ± 3	1.0	34	100.0	29	85.3	84 ± 3	7	20.6	78 ± 8	0	-	-	0	-	-
		♂ and ♀	109	108	36	22.8	85 ± 3	1.3	36	100.0	31	86.1	84 ± 3	7	19.4	78 ± 8	0	-	-	0	-	-
Total			259	255																		

(a) Alive animals after 20 weeks, when the first tumour (a leukaemia) was observed.

(b) Two or more tumours of the same and/or different types (fibroadenomas, carcinomas, sarcomas, carcinosarcomas) may be present in the same animal.

(c) Its percentages are referred to the corrected number.

(d) Average age at the onset of the first mammary tumour per animal, detected at the periodic control or at autopsy.

(e) The percentages are referred to total number of animals bearing mammary tumours.

(f) The percentages are referred to total number of animals bearing mammary tumours, histologically examined.

CONFIDENTIAL
Subject to Protective Order in
Ross v.
14th
Calcasieu Parish
700-4837

CMA 015687

TABLE 22

Experiment 57M04 : Exposure by ingestion (stomach tube) to Vinylidene Chloride (VDC) in olive oil at 0.5 cc/kg body weight, once daily, 4-5 days weekly, for 52 weeks. Results after 130 weeks (end of the experiment).


BIOLOGICAL PARAMETERS RELATED TO MAMMARY TUMOURS

Group	Animals (Designation, sex, age, 10 weeks old at start)						Age and sex of first onset of tumour (weeks)					Body weight (g)						Mortality (%)			
	Group	Designation	Animals with tumours		Animals without tumours		Total	Fibrous areas	Carcinomas	Sarcomas	Carcinomas	1 month		3 months		12 months		Animals with tumours	Animals without tumours	Animals with tumours	
			No.	%	No.	%						Animals with tumours	Animals without tumours	Animals with tumours	Animals without tumours	Animals with tumours	Animals without tumours			No.	%
130	50	48	22	45.8	26	54.2	80 ± 3	44 ± 3	83 ± 1	-	-	273	259	307	321	351	376	104 ± 3	20 ± 3	4	35.2
130 (Total)	77	77	34	44.2	43	55.8	83 ± 3	84 ± 3	78 ± 8	-	-	280	281	306	317	362	358	104 ± 3	75 ± 3	0	-

Alive animals after 20 weeks, when the first tumour (a leukaemia) was observed.

CMA 015688

CONFIDENTIAL
Subject is confidential in
Ross V. 1411
Classified Exempt



Experiment 27102 : Experiment by inhalation to Vinylidene Chloride (VDC) in air at 200, 100, 25, 10 ppm, 4 hours daily, 4-5 days weekly, for 52 weeks. Results after 121 weeks (end of the experiment).

DISTRIBUTION OF THE MALIGNANT TUMORS OF TUMORS

(first)

GROUPS NO.	TREATMENT		ANIMALS (100% of mice 16 weeks old (Grp I, II, III, IV, V, VI) and 9 weeks old (Grp VII, VIII, IX, X, XI, XII) at start)		ANIMALS WITH TUMORS						
	CONCENTRATION	LENGTH	Sex	Mount start	Kidney Adenocarcinoma				Hepatic Tumors		
					Corrected No. of (a)	No.	%	Average latency time (weeks) (b)	Corrected number (c)	No.	%
I	200 ppm	2 days	♂	60	1	0	-	-	6	0	-
			♀	60	25	0	-	-	53	1	1.9
			♂ and ♀	120	29	0	-	-	59	1	1.7
II	100 ppm	2 days	♂	30	12	0	-	-	21	0	-
			♀	30	13	0	-	-	28	3	10.7
			♂ and ♀	60	23	0	-	-	49	3	6.1
III	50 ppm	1 week	♂	30	17	1	5.9	6.4	27	0	-
			♀	30	14	0	-	-	28	2	7.1
			♂ and ♀	60	31	1	3.2	6.4	55	2	3.6
IV	25 ppm	52 weeks	♂	30	21	3	11.3	71 ± 5	29	0	-
			♀	30	26	0	-	-	30	4	13.3
			♂ and ♀	60	47	3	6.4	71 ± 5	59	4	6.8
IV bis	25 ppm	52 weeks	♂	120	98	25	20.5	75 ± 2	117	1	0.8
			♀	120	112	1	0.9	77	118	12	10.2
			♂ and ♀	240	210	26	12.4	75 ± 2	235	13	5.5
V	10 ppm	52 weeks	♂	30	25	0	-	-	30	0	-
			♀	30	26	0	-	-	30	6	20.0
			♂ and ♀	60	51	0	-	-	60	6	10.0
VI	No treatment (Controls)		♂	100	55	0	-	-	92	1	1.1
			♀	100	73	0	-	-	97	2	2.1
			♂ and ♀	200	128	0	-	-	189	3	1.6
VII	No treatment (Controls)		♂	50	70	0	-	-	80	0	-
			♀	50	65	0	-	-	88	1	1.1
			♂ and ♀	100	135	0	-	-	168	1	0.6
Total											

(a) Alive animals when the first tumor was observed : 55 weeks; mammary tumour : 27 weeks; subcutaneous adenoma : 36 weeks; leukemia : 12 weeks. The percentages are referred to the corrected number. The percentages of total are referred to the animals still alive at the 12th week, when the first tumor (a 30 g. rat) was observed.

(b) Average time from the start of the experiment to the observation (at the periodic control or at autopsy).

CONFIDENTIAL

Subject to Protective Order in
Ross v. General, Inc., No. 90-4967
14th Judicial District Court
Calcasieu Parish, Louisiana

CHA 015689

Experiment 21002. Exposure of *Chironomus tentans* (Zett.) in air at 200, 300, 400, 500, 600, 700, 800, 900, 1000, 1100, 1200, 1300, 1400, 1500, 1600, 1700, 1800, 1900, 2000, 2100, 2200, 2300, 2400, 2500, 2600, 2700, 2800, 2900, 3000, 3100, 3200, 3300, 3400, 3500, 3600, 3700, 3800, 3900, 4000, 4100, 4200, 4300, 4400, 4500, 4600, 4700, 4800, 4900, 5000, 5100, 5200, 5300, 5400, 5500, 5600, 5700, 5800, 5900, 6000, 6100, 6200, 6300, 6400, 6500, 6600, 6700, 6800, 6900, 7000, 7100, 7200, 7300, 7400, 7500, 7600, 7700, 7800, 7900, 8000, 8100, 8200, 8300, 8400, 8500, 8600, 8700, 8800, 8900, 9000, 9100, 9200, 9300, 9400, 9500, 9600, 9700, 9800, 9900, 10000, 10100, 10200, 10300, 10400, 10500, 10600, 10700, 10800, 10900, 11000, 11100, 11200, 11300, 11400, 11500, 11600, 11700, 11800, 11900, 12000, 12100, 12200, 12300, 12400, 12500, 12600, 12700, 12800, 12900, 13000, 13100, 13200, 13300, 13400, 13500, 13600, 13700, 13800, 13900, 14000, 14100, 14200, 14300, 14400, 14500, 14600, 14700, 14800, 14900, 15000, 15100, 15200, 15300, 15400, 15500, 15600, 15700, 15800, 15900, 16000, 16100, 16200, 16300, 16400, 16500, 16600, 16700, 16800, 16900, 17000, 17100, 17200, 17300, 17400, 17500, 17600, 17700, 17800, 17900, 18000, 18100, 18200, 18300, 18400, 18500, 18600, 18700, 18800, 18900, 19000, 19100, 19200, 19300, 19400, 19500, 19600, 19700, 19800, 19900, 20000, 20100, 20200, 20300, 20400, 20500, 20600, 20700, 20800, 20900, 21000, 21100, 21200, 21300, 21400, 21500, 21600, 21700, 21800, 21900, 22000, 22100, 22200, 22300, 22400, 22500, 22600, 22700, 22800, 22900, 23000, 23100, 23200, 23300, 23400, 23500, 23600, 23700, 23800, 23900, 24000, 24100, 24200, 24300, 24400, 24500, 24600, 24700, 24800, 24900, 25000, 25100, 25200, 25300, 25400, 25500, 25600, 25700, 25800, 25900, 26000, 26100, 26200, 26300, 26400, 26500, 26600, 26700, 26800, 26900, 27000, 27100, 27200, 27300, 27400, 27500, 27600, 27700, 27800, 27900, 28000, 28100, 28200, 28300, 28400, 28500, 28600, 28700, 28800, 28900, 29000, 29100, 29200, 29300, 29400, 29500, 29600, 29700, 29800, 29900, 30000, 30100, 30200, 30300, 30400, 30500, 30600, 30700, 30800, 30900, 31000, 31100, 31200, 31300, 31400, 31500, 31600, 31700, 31800, 31900, 32000, 32100, 32200, 32300, 32400, 32500, 32600, 32700, 32800, 32900, 33000, 33100, 33200, 33300, 33400, 33500, 33600, 33700, 33800, 33900, 34000, 34100, 34200, 34300, 34400, 34500, 34600, 34700, 34800, 34900, 35000, 35100, 35200, 35300, 35400, 35500, 35600, 35700, 35800, 35900, 36000, 36100, 36200, 36300, 36400, 36500, 36600, 36700, 36800, 36900, 37000, 37100, 37200, 37300, 37400, 37500, 37600, 37700, 37800, 37900, 38000, 38100, 38200, 38300, 38400, 38500, 38600, 38700, 38800, 38900, 39000, 39100, 39200, 39300, 39400, 39500, 39600, 39700, 39800, 39900, 40000, 40100, 40200, 40300, 40400, 40500, 40600, 40700, 40800, 40900, 41000, 41100, 41200, 41300, 41400, 41500, 41600, 41700, 41800, 41900, 42000, 42100, 42200, 42300, 42400, 42500, 42600, 42700, 42800, 42900, 43000, 43100, 43200, 43300, 43400, 43500, 43600, 43700, 43800, 43900, 44000, 44100, 44200, 44300, 44400, 44500, 44600, 44700, 44800, 44900, 45000, 45100, 45200, 45300, 45400, 45500, 45600, 45700, 45800, 45900, 46000, 46100, 46200, 46300, 46400, 46500, 46600, 46700, 46800, 46900, 47000, 47100, 47200, 47300, 47400, 47500, 47600, 47700, 47800, 47900, 48000, 48100, 48200, 48300, 48400, 48500, 48600, 48700, 48800, 48900, 49000, 49100, 49200, 49300, 49400, 49500, 49600, 49700, 49800, 49900, 50000, 50100, 50200, 50300, 50400, 50500, 50600, 50700, 50800, 50900, 51000, 51100, 51200, 51300, 51400, 51500, 51600, 51700, 51800, 51900, 52000, 52100, 52200, 52300, 52400, 52500, 52600, 52700, 52800, 52900, 53000, 53100, 53200, 53300, 53400, 53500, 53600, 53700, 53800, 53900, 54000, 54100, 54200, 54300, 54400, 54500, 54600, 54700, 54800, 54900, 55000, 55100, 55200, 55300, 55400, 55500, 55600, 55700, 55800, 55900, 56000, 56100, 56200, 56300, 56400, 56500, 56600, 56700, 56800, 56900, 57000, 57100, 57200, 57300, 57400, 57500, 57600, 57700, 57800, 57900, 58000, 58100, 58200, 58300, 58400, 58500, 58600, 58700, 58800, 58900, 59000, 59100, 59200, 59300, 59400, 59500, 59600, 5



DISTRIBUTION OF THE DIFFERENT TYPES OF HEPATOLANGIOMAS ("TUMORS") TUMORS

GROUPS	SEX	ANIMALS SHOWING OTHER TUMORS				Total
		Benign		Malignant		
		No.	Distribution of histotypes	No.	Distribution of histotypes	
I	♂	0		0		0
	♀	2	2 angiomas of the uterus	0		2
II	♂	0		0		0
	♀	1	1 liver angioma	2	1 salivary gland carcinoma 1 angiosarcoma of the uterus	3
III	♂	0		0		0
	♀	2	1 subcutaneous angioma 1 angioma of the uterus	1	1 hepatocarcinoma	3
IV	♂	0		1	1 subcutaneous fibrosarcoma	1
	♀	7	1 subcutaneous angioma 1 Harderian gland adenoma 1 forestomach papilloma 1 spleen angioma 2 angiomas of the uterus	2	1 subcutaneous rhabdomyosarcoma 1 interscapular fat pad angiosarcoma	9
IV Dis	♂	5	2 hepatomas 1 liver angioma 2 kidney adenomas	2	1 lymph gland carcinoma 1 subcutaneous rhabdomyosarcoma	7
	♀	7	1 subcutaneous angioma 1 hepatoma 1 liver angioma 2 spleen angiomas 2 angiomas of the uterus	3	1 carcinoma of the uterus 3 leiomyosarcomas of the uterus	11
V	♂	0		1	1 dermal fibrosarcoma	1
	♀	3	1 pituitary gland adenoma 1 spleen angioma 1 leiomyoma of the uterus	1	1 subcutaneous rhabdomyosarcoma 2 sarcomas of the uterus	6
VI	♂	2	1 hepatoma 1 spleen angioma	1	1 kidney angiosarcoma	3
	♀	1	1 liver angioma	1	1 leiomyosarcoma of the uterus	2
VII	♂	0		1	1 hepatocarcinoma	1
	♀	3	1 liver angioma 2 spleen angiomas	1	1 subcutaneous rhabdomyosarcoma	4

CONFIDENTIAL

Subject: Protective Order in
Ross v. [redacted] 137
14th Judicial District
Calcasieu Parish, Louisiana

CMA 015691

TABLE 25

Experiment BT402 : Exposure by inhalation to Vinylidene Chloride (VDC) in air at 200, 100, 50, 25, 10 ppm, 4 hours daily, 4-5 days weekly, for 52 weeks.
Results after 121 weeks (end of the experiment).

DISTRIBUTION OF THE DIFFERENT TYPES OF MAMMARY TUMOURS

(first part)


GROUP NO.	TREATMENT		ANIMALS (Swiss mice 16 weeks old (Grs I, II, III, IV, V, VI) and 9 weeks old (Grs IV bis, VII) at start)			MAMMARY TUMOURS (b)																	
	CONCENTRATION	LENGTH				Histologically examined																	
			Sex	No. at start	Corrected number (a)	Total No.	X (c)	Average latency time (weeks) (d)	No. of tumours/tumours bearing animals	Total No.	X (e)	Histotype											
												Fibromas and fibroadenomas			Carcinomas			Sarcomas			Carcinosarcomas		
											Total No.	% (f)	Average latency time (weeks) (d)	Total No.	% (F)	Average latency time (weeks) (d)	Total No.	% (f)	Average latency time (weeks) (d)	Total No.	% (f)	Average latency time (weeks) (d)	
I	200 ppm	2 days	♂	60	6	0	-	-	0	0	-	0	-	-	0	-	-	0	-	-	0	-	-
			♀	60	53	1	1.9	87	1.0	1	100.0	0	-	-	1	100.0	87	0	-	-	0	-	-
			♂ and ♀	120	59	1	1.7	87	1.0	1	100.0	0	-	-	1	100.0	87	0	-	-	0	-	-
II	100 ppm	2 days	♂	30	21	0	-	-	0	0	-	0	-	-	0	-	-	0	-	-	0	-	-
			♀	30	23	1	10.7	45 ± 5	1.0	3	100.0	0	-	-	3	100.0	45 ± 5	0	-	-	0	-	-
			♂ and ♀	60	43	1	6.1	46 ± 5	1.0	3	100.0	0	-	-	3	100.0	46 ± 5	0	-	-	0	-	-
III	50 ppm	1 week	♂	30	27	0	-	-	0	0	-	0	-	-	0	-	-	0	-	-	0	-	-
			♀	30	26	2	7.1	39 ± 13	1.0	2	100.0	0	-	-	2	100.0	39 ± 13	0	-	-	0	-	-
			♂ and ♀	60	53	2	3.6	39 ± 13	1.0	2	100.0	0	-	-	2	100.0	39 ± 13	0	-	-	0	-	-
IV	25 ppm	52 weeks	♂	30	29	0	-	-	0	0	-	0	-	-	0	-	-	0	-	-	0	-	-
			♀	30	30	4	13.3	68 ± 11	1.0	4	100.0	0	-	-	4	100.0	68 ± 11	0	-	-	0	-	-
			♂ and ♀	60	59	4	6.5	68 ± 11	1.0	4	100.0	0	-	-	4	100.0	68 ± 11	0	-	-	0	-	-
IV bis	25 ppm	52 weeks	♂	120	117	1	0.3	16	1.0	1	100.0	0	-	-	1	100.0	16	0	-	-	0	-	-
			♀	120	110	12	10.2	69 ± 4	1.0	12	100.0	0	-	-	12	100.0	69 ± 4	0	-	-	0	-	-
			♂ and ♀	240	227	13	5.5	67 ± 4	1.0	13	100.0	0	-	-	13	100.0	67 ± 4	0	-	-	0	-	-
V	10 ppm	52 weeks	♂	30	30	0	-	-	0	0	-	0	-	-	0	-	-	0	-	-	0	-	-
			♀	30	30	6	20.0	63 ± 5	1.0	6	100.0	0	-	-	6	100.0	63 ± 5	0	-	-	0	-	-
			♂ and ♀	60	60	6	10.0	63 ± 5	1.0	6	100.0	0	-	-	6	100.0	63 ± 5	0	-	-	0	-	-
VI	No treatment (Controls)	52 weeks	♂	100	97	1	1.1	25	1.0	1	100.0	1	100.0	25	0	-	-	0	-	-	0	-	-
			♀	100	97	2	2.1	49 ± 7	1.0	2	100.0	0	-	-	2	100.0	49 ± 7	0	-	-	0	-	-
			♂ and ♀	200	194	3	1.6	41 ± 9	1.0	3	100.0	1	100.0	25	2	100.0	49 ± 7	0	-	-	0	-	-
VII	No treatment (Controls)	52 weeks	♂	50	50	0	-	-	0	0	-	0	-	-	0	-	-	0	-	-	0	-	-
			♀	50	58	1	1.1	83	1.0	1	100.0	0	-	-	1	100.0	83	0	-	-	0	-	-
			♂ and ♀	100	108	1	0.6	83	1.0	1	100.0	0	-	-	1	100.0	83	0	-	-	0	-	-
Total																							

CMA 015692

CONFIDENTIAL
Subject to Protective Order in
Ross v. General Electric, No. 80-1837
14th J. 11-1-81
Caledonian Printing, London

TABLE 25

Experiment BT402 : Exposure by inhalation to Vinylidene Chloride (VDC) in air at 200, 100, 50, 25, 10 ppm, 4 hours daily, 4-5 days weekly, for 52 weeks. Results after 121 weeks (end of the experiment).



DISTRIBUTION OF THE DIFFERENT TYPES OF MAMMARY TUMOURS

(second part)

- (a) Alive animals after 27 weeks, when the first tumour (a mammary carcinoma) was observed.
- (b) Two or more tumours of the same and/or different type (fibroadenomas, carcinomas, sarcomas and carcinosarcomas) may be present in the same animal.
- (c) The percentages are referred to the corrected number.
- (d) Average age at the onset of the first mammary tumour per animal detected at the periodic control or at autopsy.
- (e) The percentages are referred to total number of animals bearing mammary tumours.
- (f) The percentages are referred to total number of animals bearing mammary tumours, histologically examined.

Draft

CONFIDENTIAL

Subject to Protective Order in
 Ross v. Centro, Inc., No. 00-1337
 14th Street, N.W., Washington, D.C.
 Calcasieu Parish, Louisiana

CMA 015693

TABLE 26

Experiment BT405 : Exposure by inhalation to Vinylidene Chloride (VDC), in air at 25 ppm, 4 hours daily, 4-5 days weekly, for 52 weeks.
Results after 157 weeks (end of the experiment).

GROUPS NO.	CONCENTRATION	ANIMALS (Chinese hamsters, 28 weeks old at start)			ANIMALS WITH TUMOURS						
		Sex	No. at start	Corrected number (a)	Carcinomas of the uterus			Others tumours	Total		
					No.	% (b)	Average latency time (weeks)(c)		No.	% (b)	Mean No. of different tu- mours/tumours bearing ani- mals
I	25 ppm	♂	30	17				0	0	-	0
		♀	30	22	6	27.3	108 ± 8	2 (d)	7	31.8	1.1
		♂ and ♀	60	39				2	7	17.9	1.1
II	No treatment (Controls)	♂	18	16				0	0	-	0
		♀	17	11	6	54.5	95 ± 12	1 (e)	7	63.6	1.0
		♂ and ♀	35	27				1	7	25.9	1.0
Total			95	66							

a) Alive animals after 63 weeks, when the first tumour (a carcinoma of uterus) was observed.

b) The percentages are referred to the corrected number.

c) Autopsy finding (from start of experiment to death).

d) 1 skin carcinosarcoma; 1 ovary thecoma.

e) 1 skin carcinoma.

CONFIDENTIAL
Subject to Protective Order in
Ross v. U.S. Dept. of Health, No. 90-4437
14th U.S. Circuit Court of Appeals
Calcasieu Parish, Louisiana

CMA 015694

BASF Aktiengesellschaft

Attachment



21492044000
27 Sep 1978
Er:

Telefon 06211 501 (Vermittlung)
Telex 464811 basf d (Zentrale)
Telegramm: BASF Ludwigshafen
Bankverbindung: Landeszentralbank
5700 Ludwigshafen, Girokonto 545 07300

BASF 5700 Ludwigshafen

Mr. Professor
Dr. Cesare Maltoni
Direttore Istituto di
Oncologia
Viale Ercolani, 4/2
I-40138 Bologna

✓ CC J. NORRIS 9008 Highland
CC P.J. GERING 1803
CC V.K. ROWE 1803
with note F Y 1.

Ihre Zeichen	Ihre Nachricht vom	Unsere Zeichen	Telefon-Durchwahl	Telex	Ludwigshafen
		FLD/N	06211 50-	464-	
		he-mi	21391		Sept, 26th, 1978

Betreff
Statistical evaluations of the VDC studies

Dear Professor Maltoni,

as determined at our latest meeting we are now enclosing the statistical evaluation of the experiment 2 (BT 402). This paper has been discussed with Dr. Paddle from ICI.

The tables start with number 24 up to 39; additionally, the tables 30 up to 39 (survival curves) are enclosed on a film-strip.

Yours sincerely

BASF Aktiengesellschaft

Mr. Fison *Dr. Bachmann*

- Eisenträger Bakemeier
copy to:
Dr. Paddle, ICI South Lodge PO Box 3, Fulshaw Hall, Wilmslow
Cheshire SK9 1QB
Dr. T.D. Browne, ICI Castner Kellner Works, Runcorn Cheshire WA7 4JE
Dr. J.H. Wilson, ICI Plastics Division, Welwyn Garden City, Hertfordshire
Dr. A. Collard, SOLVAY & Cie. S.A. Administration General, Rue du
Prince Albert 33, B-1050 Brüssel
Dr. J. Helfenstein, DOW Chemical (Europe), Comp. S.A.
Bachtobelstr. 3, CH-8810 Horgen
Dr. L. Rinzema, DOW Chemical (Europe), Comp. S.A.
Bachtobelstr. 3, CH-8810 Horgen

WNT - J 560, Herrn Dr. H.-J. Klimisch

CONFIDENTIAL

Subject to Protective Order in
Ross v. Borden, Inc., No. 73-1000
14th U.S. District Court
California

CMA 015695

Aufsichtsratsvorsitzender: Bernhard Teim
Vorstand: Martin Seefelder, Vorsitzender;
Friedrich Ornbach; Bernhard Franz; Erich Henkel;
Reif Magener; Horst Pommer; Herbert Wiersmann;
Sitz der Gesellschaft: 5700 Ludwigshafen
Registriergericht: Amtsgericht Ludwigshafen.

4 Nov 1984 754 Lg Nr 9030200

A P P E N D I X

STATISTICAL ANALYSIS OF THE EXPERIMENT 2 (BT 402) *

Material and Methods

The data available for statistical analysis are to be seen in table 23. That is, for each group, the number of

- animals alive after 12, 27, 36 and 55 weeks
- animals with mammary adenocarcinomas (=MA)
- animals with pulmonary adenocarcinomas (=PA)

are known. In addition to this, the age (in weeks) at death and for MA the time of tumour occurrence were known for each animal in the groups IV, IV bis, V, VI and VII. These figures are available upon request. The conditions at the beginning of the experiment are listed in table 2.

Using these data the following statistical evaluations were carried out.

1. The survival rates at the intervals given in table 23, and the mean values of life time were calculated to evaluate differences between treated and control groups.
2. Tumour incidences at the end of the experiment were calculated. Additionally tumour incidences in different time intervals of the experiment were calculated to see if there are significant effects which depend on survival rates.
3. Calculations were carried out to test if a dose response relationship can be found.

* BASF Aktiengesellschaft, ICI Ltd

~~CONFIDENTIAL~~

Order in
No. 90-4837
Court
Louisiana

CMA 015696

The comparison of mean was made with a rank test of Krauth (/1/). Incidences were examined with the "Exact Test by Fisher" (/2/) and the Logrank test (/3/). For calculation concerning dose response relationship see /4/.

All statistical tests were carried out with type 1 error α of 0.05 and 0.01. A significance for $\alpha = 0.05$ is marked with *, a significance for $\alpha = 0.01$ is marked with x. Because of two control groups a C identifies the group (either VII or VI) with which the dose groups are compared.

Analysis

1.1 Survival rates for 12, 27, 36 and 55 weeks after start of treatment

The comparison of survival rates of dose groups to control groups VI and VII shows that only the groups I, II and III have significantly lower survival rates (table 24). This indicates a strong toxic effect of VDC at these doses. Therefore, the further evaluation does not include groups I, II and III.

The survival rates of the remaining dose groups are generally higher in comparison with the control groups VI and VII.

1.2 Mean value of life time

As expected from the results of the survival rate evaluations, the mean of life time of the animals in the treated groups (both male and female) is greater than in the control groups (table 25). With one exception, significant differences are only to be seen between groups which began their exposure at different ages, for instance the mean value of groups IV and V is significantly greater than the mean of the control group VII. Even when comparing the means of groups IV bis and IV (which have the same concentration but different ages at

CONFIDENTIAL
Subject to
ROSS
0-1337
21

CMA 015697

the beginning of the exposure), there is a significant difference. For these reasons, the groups were divided into two sets for further statistical evaluations:

dose groups IV, V and control VI,
dose groups IV bis and control group VII.

The survival functions of different groups are plotted in tables 30 up to 39. These diagrams show that there exists an interval for each set where the graphs have the same shape. In particular these are the intervals:

	male	female
groups IV, V, VI	90 onwards	90 onwards
groups IV BIS, VII	72 onwards	93 onwards

The tables 26 and 27 include the statistical results of a comparison of the mean value of life time as well as the incidences of MA and PA separated for each interval. The intervals above reflect the same mean value of life time, but the earlier intervals show a lower mean (significant as a rule) for the control groups in comparison with the dose groups due to an increased incidence of early deaths.

2. Comparing tumour incidences, two tests were carried out: The Exact Fisher Test and the Logrank test. The first test compares the tumours frequencies at the end of the experiment; whereas the second test takes into account differences in the survival curves.

2.1 Tumour incidences at the end of the experiment

The number of animals with any tumours in dose groups are significantly greater than in the corresponding untreated groups (table 28).

CONFIDENTIAL
Subject to Protective Order in
Ross v. ~~_____~~ No. ~~_____~~ 1983
~~_____~~ Louisiana

CMA 015698

The tumour incidence for male animals with PA is significantly greater in all dose groups than in the corresponding control groups. In female animals there is only a significantly higher tumour incidence in the two 25 ppm groups. The tumour incidence for female animals with MA is significantly greater in all treated groups than in the corresponding control groups.

2.2 Tumour incidences in different intervals of the experiment

At each interval the incidences of MA or PA respectively in dose groups are greater than the corresponding incidences in control groups, at some intervals significantly greater (tables 26,27).

2.3 Relationship between tumour incidence and survival times

Fewer of the differences between dosed and control groups are significant when the incidences of tumours are compared with the Logrank test (tables 28, 29). However the continued existence of several significant differences shows that the increases in tumour incidences in dosed animals cannot be wholly attributed to their increased life time.

3. Evaluation of dose response relationship

The PA rate of male group V (10 ppm) is higher than both 25 ppm groups IV and IV bis, in fact, in comparison to group IV bis the PA rate of male group V is significantly greater with $\alpha = 0.01$. For that reason, a reliable dose response function cannot be established. A similar result holds for female animals concerning the MA incidences.

For female PA incidences a dose response relation (probit model) could be established for the groups IV, V and VI - but there is the following limitation that at zero dose

CC
Sub
Page
1977
CMA 015699

CMA 015699

there is an effect which must be considered (key-word: Abbott's formula; see /4/). That means three parameters have to be fitted to three points so that the validity of the relationship cannot be tested.

Summary

There are significantly higher pulmonary tumour incidences in male and female mice in both of the 25 ppm dose groups. At 10 ppm only in male mice a significantly higher pulmonary tumour rate can be found with no corresponding significance in females. There are significantly higher mammary tumour incidences in female mice exposed to 10 or 25 ppm VDC.

As the dosed animals survive, on the whole, longer than the control animals, these conclusions based on crude total percentages could give a misleading impression of the effect of exposure. The use of techniques which allow for tumour incidence being age-related showed that the effects of exposure are exaggerated by the crude percentages, but that significant effects still exist between dosed and control animals.

In general no dose response relationship can be established for either the increased mammary or pulmonary tumour incidences.

The lack of a clear cut effect of VDC either in different intervals of exposure or at the completion of exposure underlines the lack of a dose response relationship.

For in
 File No. 10-4337
 15th Judicial District Court
 Calcasieu Parish, Louisiana

CMA 015700

25.9.78

References

- /1/ Krauth, J.: A locally most powerful tied rank test in a Wilcoxon Situation; Ann. Math. Statist. 42, 1949 - 1956, 1971
- /2/ Witting, H.: Mathematische Statistik; 2. Aufl. Teubner Stuttgart 1974; 173 - 177
- /3/ R. Peto, M. C. Pike, P. Armitage, N. E. Breslow, D. R. Cox, S. V. Howard, N. Mantel, K. McPherson, J. Peto and P. G. Smith: Br. J. Cancer 35, 1 - 39, 1977
- /4/ Finney, D.: Probit analysis, Cambridge University Press, 1971

Cal: St. Parish, Louisiana

CMA 015701

Subj: [redacted] in
Ross v. [redacted], in [redacted], No. 90-4837

	male					female				
Group	Animals at start	Alive animals after (week)				Animals at start	Alive animals after (week)			
		12	27	36	55		12	27	36	55
VII	90	87 C	80 C	73 C	70 C	90	89 C	88 C	86 C	85 C
VI	100	99 C	92 C	80 C	56 C	100	98 C	97 C	92 C	73 C
V	30	30	30	28	25	30	30	30	30	26
IV bis	120	120	117	113	98	120	119	118	118	112
IV	30	30	29	28	21	30	30	30	29	26
III	30	29	27	26	17 *	30	29	28	27	14 x x
II	30	23 x x	21 x x	18 x x	12 x	30	30	28	26	13 x x
I	60	9 x x	6 x x	5 x x	1 x x	60	57	53 * *	46 x x	28 x x

Table 24: Survival rates after 12, 27, 36 and 55 weeks after start of treatment (Exact Fisher Test, one-sided)

CMA 015702

57
 Calcasieu Parish, Louisiana
 1974

Group	male			female		
	Animals at start	Life time Mean Stand.Dev.		Animals at start	Life time Mean Stand.Dev.	
VII	90	70.7 C	22.58	90	81.0 C	18.51
VI	100	75.4 C	22.08	100	83.1 C	20.32
V	30	83.7 x *	15.77	30	87.5 *	12.97
IV bis	120	75.0	15.85	120	84.3	17.41
IV	30	79.6 *	17.03	30	90.0 x *	18.40

Table 25: Mean and Standard Deviation (in weeks) of life time
 (Test of Krauth, one - sided)

CONFIDENTIAL

Subject to Protective Order in
Case No. 00-4837

14-
Calnes
Alabama

CMA 015704

	male			female		
Group	VI	V	IV	VI	V	IV
Animals at start	100	30	30	100	30	30
Interval	(.1, 89)			(.1, 89)		
N	63	19	20	54	15	13
N.MA	0	0	0	2	4 *	2
N.PA	2	7 x	3	4	3	1
Mean	61.5	74.9x	71.1x	69.0	77.5x	73.1
Interval	(90,150)			(90,150)		
N	37	11	10	46	15	17
N.MA	0	0	0	0	2	2
N.PA	1	4 x	4 x	0	0	6 x
Mean	99.0	98.8	96.7	99.6	97.4	102.9

Table 26: Mean of life time and tumour incidence for MA and PA for special intervals; N ist the number of animals died in the interval; N.MA (respectively N.PA) is the number of animals with MA (respectively PA) (Exact Fisher test one-sided for tumour incidence, Test of Krauth one-sided for mean)

CONFIDENTIAL
 Report of the
 Research Committee
 on the Health of
 the People of Louisiana
 1967

	male		female	
Group	VII	IV bis	VII	IV bis
Animals at start	90	120	90	120
interval	(1, 71)		(1, 71)	
N	40	51	25	31
N.MA	0	1	0	3
N.PA	1	3	0	2
Mean	50.8	60.0 x	60.4	63.1
interval	(72,150)		(72, 92)	
N	50	69	41	56
N.MA	0	0	0	5
N.PA	2	13 *	1	3
Mean	86.7	86.1	80.4	84.5 x
interval			(93,150)	
N			24	33
N.MA			1	4
N.PA			1	6
Mean			103.7	103.8

CMA 015705

Table 27: Mean of life time and tumour incidence for MA and PA for special intervals; N is the number of animals died in the interval; N.MA (respectively N.PA) is the number of animals with MA (respectively PA) (Exact Fisher Test one-sided for tumour incidence, Test of Krauth one-sided for mean)

CONFIDENTIAL

Subject: Calcesteu Parish, Louisiana
 Ross v. Calcesteu Parish, Louisiana
 14th Jan 1957

Group	male				female			
	Animals at start	N.TU	N.MA	N.PA	Animals at start	N.TU	N.MA	N.PA
VI	100	7	0	3	100	15	2	4
V	30	11 x	0	11 x	30	15 x	6 x	3
IV	30	11 x	0	7 x	30	17 x	4 *	7 x
VII	90	7	0	3	90	12	1	2
IV bis	120	43 x	1	16 x	120	40 x	12 x	11 *

Table 28: Tumour incidence for MA and PA at the end of experiment;
 N.TU (respectively N.MA, N.PA) is the number of animals with
 tumours (respectively MA, PA) (Exact Fisher Test, one - sided).

CMA 015706

Group	male			female		
	Animals at start	N.MA	N.PA	Animals at start	N.MA	N.PA
VI	100	0	3	100	2	4
V	30	0	11 x	30	6 x	3
IV	30	0	7 x	30	4	7 *
VII	90	0	3	90	1	2
IV bis	120	1	16 *	120	12 *	11

Table 29: Tumour incidence for MA and PA at the end of experiment; N.MA (respectively N.PA) is the number of animals with MA (respectively PA) (Logrank test)

Subject
Ross v. C
14th
Calons

CMA 015707

Table 30

SURVIVAL-RATE (VDC)

GROUP : VI

MALE

CONCENTRATION ppm : 3
 FIRST TREATMENT WEEKS : 1.5
 ANIMALS AT START : 100



CONFIDENTIAL

Subject to Protective Order in
Ross v. Ciba-Geigy, No. 00-483Z
 14th Judicial District Court
 Calcasieu Parish, Louisiana

CMA 015708

Table 31

SURVIVAL-RATE (VOC)

GROUP : VI FEMALE

CONCENTRATION 1000
FIRST TREATMENT WEEKS 10
ANIMALS AT START 100





Table 32

SURVIVAL-RATE (VOC)

GROUP : V

MALE

CONCENTRATION ppm : 10
 FIRST TREATMENT WEEKS : 15
 ANIMALS AT START : 30



CONFIDENTIAL

Subject to Protective Order in
 Ross v. Ciba-Geigy, No. 83-137
 14th J. Calender, Louisiana

CMA 015710


Table 33

SURVIVAL-RATE (VOC)

GROUP : V

FEMALE

CONCENTRATION ppm : 10
FIRST TREATMENT WEEKS : 8
ANIMALS AT START : 50



Subject: CMA 015711
Ross v 14th
Calif. 14th
California

CMA 015711


Table 34

SURVIVAL-RATE (VCC)

GROUP : IV

MALE

CONCENTRATION ppm : 25
 FIRST TREATMENT WEEKS : 5
 ANIMALS AT START : 30



1957
 Rose W. Court
 Louisiana


CMA 015712

Table 35

SURVIVAL-RATE (VCC)

GROUP : IV FEMALE

CONCENTRATION, PPM : 25
FIRST TREATMENT WEEKS : 15
ANIMALS AT RISK : 30



CONFIDENTIAL

Subject to Protective Order in
Ross v. [redacted] 1:837
[redacted] int
Calcasieu Parish, Louisiana


CMA 015713

Table 36

SURVIVAL-RATE (VOC)

GROUP : VII MALE

CONCENTRATION ppm : 3
FIRST TREATMENT WEEKS : 3
ANIMALS AT START : 30



Subject: 1837
Ross v. Court
 14-10-57
 Calcasieu Parish, Louisiana


CMA 015714

Table 37

SURVIVAL-RATE (VOC)

GROUP : VII FEMALE

CONCENTRATION PPM : 3
FIRST TREATMENT WEEKS : 3
ANIMALS AT START : 30



CONFIDENTIAL
Submitted in
Ross v. Conoco, Inc., No. 00-4837
14th Judicial District Court
Calcasieu Parish, Louisiana


CMA 015715

Table 38

SURVIVAL-RATE (VOC)

GROUP : IV 315 MALE

CONCENTRATION ppm : 25
FIRST TREATMENT WEEKS : 3
ANIMALS AT START : 120



CONFIDENTIAL
Subject to Protection in
Ross v. Conoco, No. 10-4532
14th Judicial District Court
Calcasieu Parish, Louisiana

CMA 015716

Table 39

SURVIVAL-RATE (VOC)

GROUP : IV 313 FEMALE

CONCENTRATION ppm : 25
 FIRST TREATMENT WEEKS : 3
 ANIMALS AT START : 120



CONFIDENTIAL
 Subject: ... Order in
 Case No. ... 90-4837
 1st Judicial District Court
 Calcasieu Parish, Louisiana

CMA 015717